annual report 2014 - 2015
Swiss Childhood Cancer Registry
Annual Report 2014 /2015
For the Swiss Childhood Cancer Registry
Verena Pfeiffer
Shelagh Redmond
Rahel Kuonen
Grit Sommer
Ben Spycher
Matthias Schindler
Parvinder Singh
Gisela Michel
Claudia Kuehni
For the Swiss Paediatric Oncology Group
Felix Niggli
Heinz Hengartner
Maja Beck Popovic
Nicolas von der Weid
Isabelle Lamontagne - Müller
Bern, June 2016
Publisher:
Swiss Childhood Cancer Registry
Claudia E. Kuehni
Address:
Institute of Social and Preventive Medicine
University of Bern
Finkenhubelweg 11
CH - 3012 Bern
Switzerland
Tel. +41 (0)31 631 56 70
Tel. +41 (0)31 631 38 99
E - mail: kinderkrebsregister@ispm.unibe.ch
www.childhoodcancerregistry.ch
www.kinderkrebsregister.ch
www.registretumeursenfants.ch
www.registrotumouripediatrici.ch
Bern, Swiss Childhood Cancer Registry
4
Table of contents
1. Introduction
7
2. Organisation of the Swiss Childhood Cancer Registry
9
2.1 Institute of Social and Preventive Medicine (ISPM), University of Bern
9
2.2 Swiss Paediatric Oncology Group (SPOG)
10
2.3 General information
11
3. Routine Analyses
13
3.1 Overview
13
3.2 All cases registered in the SCCR (N = 9353)
13
3.3 Swiss residents aged 0 - 14 years at diagnosis (N = 6604)
15
3.4 Swiss residents aged 15 - 20 years at diagnosis (N = 501)
21
4. Research on childhood cancer
23
4.1 Aetiology of childhood cancer
25
4.2 Long - term outcomes
26
4.3 International collaborations
28
4.4 Psychosocial outcomes and follow-up care
30
5. Publications of the Swiss Childhood Cancer Registry
31
5.1 Original articles (Peer reviewed journals)
31
5.2 Editorials, commentaries and author replies (Peer reviewed journals)
34
5.3 Reviews (Peer reviewed journals)
34
5.4 Publications (other journals)
35
5.5 Reports
36
6. Appendix: Classification of cancer diagnoses
37
5
6
1. Introduction
The Swiss Childhood Cancer Registry (SCCR) is the national
population - based cancer registry for children and adolescents
in Switzerland. New cancer diagnoses, clinical information, details on treatment and long - term follow - up (survival, second
primary neoplasms and late effects) have been registered in
the SCCR since 1976. This year, 2016, the SCCR celebrates
its 40th birthday! With many associated research projects and
through close collaboration with clinicians it contributes to
understanding the causes of cancer in children, improving follow - up care and reducing late effects.
The SCCR is located at the Institute of Social and Preventive Medicine (ISPM) at the University of Bern. It is operated
jointly by the Swiss Paediatric Oncology Group (SPOG) and the
University of Bern. Since 1976, all nine Swiss paediatric haematology - oncology centres report newly diagnosed cases to the
registry and send annual updates on clinical follow - up. Since
2007, the SCCR also collects supplementary data from other
sources, including cantonal cancer registries, other hospitals,
pathology laboratories and the Swiss Federal Statistical Office
(SFSO). As of 31st December 2014, data from 9353 cases (diagnosed in 9225 patients) have been registered.
The SCCR is authorized to collect non - anonymised data.
The permission has been issued in 2007 by the Federal Commission of Experts for Professional Secrecy in Medical Research
(Eidgenössische Expertenkommission für das Berufsgeheimnis
in der medizinischen Forschung). Since 2014 the new act on
human research is in place. The SCCR got a new authorization
issued by the ethics committee of the canton of Bern in July
2014.
This seventh report covers the routine analyses of all children diagnosed between 1st January 1976 and 31st December
2014. Activities, research and publications of the SCCR are described for the years 2014 to 2016. The report contains:
• An overview of the organisation and team of the SCCR,
SPOG and the participating paediatric haematology oncology centres (Chapter 2)
• A summary of the data collected in the registry up to 31st
December 2014 (Chapter 3)
• A summary of current research of the SCCR (Chapter 4)
• A list of publications (Chapter 5)
Our website (www.childhoodcancerregistry.ch) contains
further information, including past annual reports and scientific publications.
We would like to thank all the children and their families,
and all adolescent and adult childhood cancer survivors, for
allowing us to collect their data. We also thank the physicians
and clinical research coordinators of the Swiss Paediatric Oncology Group for their excellent collaboration. Our thanks also
go to the cantonal cancer registries, the National Institute for
Cancer Epidemiology and Registration (NICER), the Swiss Federal Statistical Office (SFSO), the Federal Office of Public Health
(FOPH) and the pathology laboratories for their cooperation.
Finally, we thank our supporters for their generous contributions.
The SCCR is an associated member of the National Institute for Cancer Epidemiology and Registration (NICER), of
the European Network of Cancer Registries (ENCR) and of the
International Association of Cancer Registries (IACR), and collaborates with childhood cancer registries throughout Europe.
What did the Swiss Childhood Cancer Registry achieve
in 40 years?
• Performed national childhood cancer monitoring of high
quality
• Provided reliable statistical routine data
• Established a competitive research platform
• Gave competent ad hoc answers to health-, environmental-,
socio- , political- related questions
• Cooperated closely with all paediatric oncologists,
• Established a strong network with Swiss parents organisations
Swiss Childhood Cancer Registry Annual Report 2014/2015
lntroduction
7
8
2. Organisation of the Swiss Childhood Cancer Registry
The Swiss Childhood Cancer Registry (SCCR) is a member of the Swiss Paediatric Oncology Group (SPOG) and is organised as a joint operation of the Institute of Social and Preventive Medicine (ISPM) at the University of Bern and the
SPOG.
2.1 Institute of Social and Preventive Medicine (ISPM), University of Bern
Swiss Childhood Cancer Registry
Institute of
Social and Preventive Medicine
Finkenhubelweg 11
CH - 3012 Bern
Switzerland
Tel. +41 (0)31 631 56 70
www.childhoodcancerregistry.ch
Direction
Claudia Kuehni, Prof MD
Head of SCCR
claudia.kuehni@ispm.unibe.ch
Gisela Michel, Prof PhD
Vice head of SCCR
gisela.michel@unilu.ch
Swiss Childhood Cancer Registry
Verena Pfeiffer, PhD
Project coordinator SCCR
verena.pfeiffer@ispm.unibe.ch
Katharina Flandera
Administration
katharina.flandera@ispm.unibe.ch
Shelagh Redmond, PhD
Diagnostic coding, data quality
Parvinder Singh
Statistics
Meltem Altun
Data management
Erika Brantschen
Data management
Trust Centre
Christina Krenger
Data management
Informatics and database support
Priska Wölfli
Database support
Research projects
Ben Spycher, PhD
Senior research fellow, Project manager
Grit Sommer, PhD
Senior research fellow, Project manager
Rahel Kuonen, MSc
Senior research fellow, Project manager
Christian Kreis, PhD
Senior research fellow
Fabien Belle, MSc
PhD student
Konstantinoudis Garyfallos, MSc PhD student
Rahel Kasteler, MD
PhD student
Matthias Schindler, MSc
PhD student
Annette Weiss, MSc
PhD student
Swiss Childhood Cancer Registry Annual Report 2014/2015
Organisation of the Swiss Childhood Cancer Registry
9
2.2 Swiss Paediatric Oncology Group (SPOG)
SPOG Office
Effingerstrasse 33, 3008 Bern
Tel.: +41 (0)31 508 42 33
www.spog.ch
SPOG Executive Board
Felix Niggli, Prof MD
President
Heinz Hengartner, MD
Vice president
Maja Beck Popovic, Prof MD
Committee Member
SPOG Office in Bern
Isabelle Lamontagne - Müller, MSc
Managing director
Marlise Rohrer
Director’s assistant
Barbara Böttcher, PhD
Head Quality assurance
Julia Ruckstuhl, MSc
Head Regulatory affairs
Tu- My Diep Lai, PhD
Regulatory affairs
Martina Peluso, MSc
Regulatory affairs
Silvia Wirth, PhD
Quality assurance
Regulatory affairs
isabelle.lamontagne@spog.ch
Participating centres (paediatric haematology - oncology)
Head of Division
Clinical Research Coordinator
Aarau
Kinderklinik, Kantonsspital Aarau
R. Angst, MD
C. Anderegg, MSc
Basel
Universitäts - Kinderspital
beider Basel [UKBB]
N. von der Weid, Prof MD
V. Stahel
M. Imbach
Bern
Universitätsklinik für
Kinderheilkunde, Inselspital
K. Leibundgut, Prof MD
F. Julmy
N. Beusch
Genève
Hôpital des Enfants, Hôpitaux
Universitaires de Genève [HUG]
M. Ansari, Prof MD
R. Lo Piccolo
V. Mattiello, MD
Lausanne
Service de Pédiatrie, Centre Hospitalier M. Beck Popovic, Prof MD R. - E. Garcia, MD
Universitaire Vaudois [CHUV]
E. Lemmel
Bellinzona
Reparto di Pediatria, Ospedale
S. Giovanni, Bellinzona
P. Brazzola, MD
P. Brazzola, MD
P. Balestra
Luzern
Kinderspital, Kantonsspital Luzern
J. Rischewski, PD MD
N. Lanz
St.Gallen
Ostschweizer Kinderspital
J. Greiner - Lang, MD
F. Hochreutener
A. Schiltknecht
F. Niggli, Prof MD
M. Grotzer, Prof MD
H. Markiewicz
A. Reinberg
R. Siegenthaler
C. Althaus, MD
Zürich
Universitäts - Kinderspital, Zürich
10
2.3 General information
Aims
The Swiss Childhood Cancer Registry collects information
on the diagnosis, treatment and follow-up of children and adolescents with cancer in Switzerland, and provides data for national and international statistics and research projects.
It aims:
• To collect representative, population- based data on
cancer in children and adolescents in Switzerland (cancer
incidence, prevalence, time trends, regional distribution
and survival rates)
• To document diagnostic evaluations, treatment and
participation in clinical trials
• To describe short- term and long- term prognosis (mortality, morbidity and quality of life) after cancer in childhood
and adolescence
• To provide a research platform for clinical, epidemiological and basic research
It thus contributes to:
• Research into the aetiology of cancer in children and
adolescents
• Planning of health services
• Continuous improvement of treatment
• Identifying possible late effects of therapy, with the aim
to diagnose and treat them early and prevent them in
the future
Inclusion criteria
The SCCR registers all children and adolescents aged 0 to
20 years, resident or treated in Switzerland, diagnosed with:
• Acute and chronic leukaemias, including myelodysplastic
syndrome
• Lymphomas
• Malignant solid tumours
• Central nervous system tumours (CNS), malignant and
benign tumours
• Langerhans cell histiocytosis (LCH),
Hemophagocytic lymphohistiocytosis (HLH)
Since 2014 it also registers children and adolescents diagnosed
with:
•
•
•
•
•
Aggressive fibromatosis (ICD - O - 3M code 8821 /1)
Benign /mature teratoma (ICD - O - 3M code 9080 /0)
Mesoblastic nephroma (ICD - O - 3M code 8960 /1)
Severe aplastic anaemia (ICD - 10 D61.9)
Neoplasms of the liver, histologically proven, but no
malformations
Children and adolescents who are not Swiss residents but
are diagnosed or treated in Switzerland are registered, but they
are excluded from analyses of incidence and survival.
Swiss Childhood Cancer Registry Annual Report 2014/2015
Sources of data
Data on children and adolescents with cancer are collected from several sources, including:
• The nine Swiss centres for paediatric oncology and haematology (Chapter 2.2)
• Other hospitals
• Cantonal cancer registries, represented by the National
Institute for Cancer Epidemiology and Registration
(NICER)
• Clinical and epidemiological registries (e.g. brain tumour
registry, bone tumour registry, Swiss growth registry etc.)
• The Swiss Federal Statistical Office (SFSO; Swiss mortality
statistics)
• Pathology laboratories
Most children are reported by one of the nine Swiss centres for paediatric oncology and haematology. Local clinical
research coordinators complete forms for all newly diagnosed
patients. Basic information on diagnosis is later completed with
information on treatments, remissions, relapses, transplantations and health outcomes. These forms are sent to the SCCR
and information is entered into the database. Important medical documents (e.g. pathology reports) are scanned and stored
electronically using a pseudonym. Paper copies are destroyed.
Information on Swiss residency is validated through municipal
population registers.
For the first five to ten years after diagnosis follow- up data
is extracted annually from patients’ hospital records by the local clinical research coordinators in all paediatric oncology and
haematology centres (Chapter 3.3). To assess outcomes after
the children have left the clinic, patients are contacted directly
with a questionnaire and data is linked to mortality records
(SFSO) and to records from cantonal cancer registries (Chapter
4.2). Life status update is assessed through community registries. For children not treated in a paediatric oncology and
haematology centre, clinical follow- up from hospitals is often
not available, but long- term epidemiological follow- up is done
via questionnaires and by assessment of second primary neoplasms and mortality as for the other patients and life status
update via community registries (Chapter 3.3).
Clinical database
The current SCCR database was set up in 2007. The following information is routinely collected:
• Tumour diagnosis, date of diagnosis, morphology, topography, stage, metastases
• Other diagnoses (cancer- relevant pre- existing conditions)
• Relevant laboratory and clinical data
• Treatment (clinical trial participation, chemotherapy, radiotherapy, surgical intervention, bone marrow transplantation) and treatment centres involved
• Follow- up data (changes of treatment, remissions, relapses, survival /death and cause of death)
• Late adverse outcomes (e.g. cardiovascular diseases,
second primary neoplasms and endocrine disorders)
Organisation of the Swiss Childhood Cancer Registry
11
Trust centre
Data protection
Since 2010, personal information (name and address) is
stored in a separate database in the trust centre. The trust centre validates addresses, residence status, nationality, and vital
status via community registers. This personal information is
separated strictly from clinical information of the SCCR database. The following data is collected:
In 2004, the SCCR received a special authorisation (Sonderbewilligung) from the Swiss Federal Commission of Experts
for Professional Secrecy in Medical Research. Starting from
June 2007, a general authorization (Registerbewilligung) ) permitted the data collection from paediatric cancer patients (children and adolescents) throughout Switzerland after obtaining
written, oral or silent consent.
• Patient name, address of residence at time of diagnosis,
current address of residence
• Date of birth, sex, first language
• Country of residence and nationality at time of diagnosis
• Vital status and date of death
• Parental profession, parental date of birth
Tumour coding
All tumours are coded according to the following international classification systems (see appendix):
• International Classification of Childhood Cancer, third
edition (ICCC - 3)
• International Classification of Diseases for Oncology,
third edition (ICD - O - 3)
• International Classification of Diseases and Related
Health Problems, tenth revision (ICD - 10)
In the annual report, the main diagnostic groups of the ICCC - 3
are used:
I.
Leukaemias, myeloproliferative diseases, and myelodysplastic diseases
II. Lymphomas and reticuloendothelial neoplasms
III. CNS and miscellaneous intracranial and intraspinal
neoplasms
IV. Neuroblastoma and other peripheral nervous cell tumours
V. Retinoblastoma
VI. Renal tumours
VII. Hepatic tumours
VIII. Malignant bone tumours
IX. Soft tissue and other extraosseous sarcomas
X. Germ cell tumours, trophoblastic tumours, and
neoplasms of gonads
XI. Other malignant epithelial neoplasms and malignant
melanomas
XII. Other specified and unspecified malignant neoplasms
Langerhans cell histiocytosis (LCH), which is not included in
ICCC - 3, is reported separately.
12
Since January 2014 the new Human Research Act and its
three ordinances are in place. Out of those three ordinances,
the ordinance on Human Research with the exception of Clinical Trials provides the new framework for the SCCR. Instead
of the Swiss Federal Commission of Experts for Professional
Secrecy in Medical Research, data collection and storage by
SCCR now require an authorisation by the ethics committee of
the canton of Bern. The general authorization (Registerbewilligung) has been replaced in July 2014 by an approval from the
ethics committee of the canton of Bern.
Funding
The SCCR thanks the following supporters for their financial contributions towards the daily operation and the continuous development of the registry. Supporters of scientific
research of the SCCR are listed in Chapter 4.
Main funding sources 2014 /2015
• Schweizerische Konferenz der kantonalen Gesundheitsdirektoren und - direktorinnen (GDK)
• Schweizerische Pädiatrische Onkologie Gruppe (SPOG)
• Universität Bern, Institut für Sozial- und Präventivmedizin
(ISPM)
• Krebsforschung Schweiz
• Kinderkrebshilfe Schweiz
Other funding sources 2014 /2015
• National Institute for Cancer Epidemiology and
Registration (NICER)
• Federal Office of Health (FOH)
• AXA- Winterthur
• Celgene GmbH
(through Förderverein Schweizer Kinderkrebsregister)
• Amgen Switzerland AG
(through Förderverein Schweizer Kinderkrebsregister)
• Helsana Versicherungen AG
(through Förderverein Schweizer Kinderkrebsregister)
3. Routine Analyses
3.1 Overview
3.2 All cases registered in the SCCR (N = 9353)
The SCCR registers all tumours diagnosed and treated in
Switzerland, classified according to the ICCC - 3 and Langerhans cell histiocytosis (LCH) in patients aged 0 to 20 years at
time of diagnosis. This annual report covers the time period
from 1st January 1976 until 31st December 2014. The additional disorders, which are registered since 2014 (see inclusion
criteria under paragraph 2.3), have not been included in the
following analyses. Incidence rates are calculated based on the
number of primary neoplasms (cases). The number of cases
slightly exceeds the number of patients because patients with
more than one primary tumour diagnosed before age 20 years
are counted separately for each new tumour.
This chapter describes data from all cases diagnosed
1976 - 2014, resident in Switzerland or abroad, diagnosed or
treated in Switzerland (N = 9353).
The section on routine analyses includes three chapters:
Chapter 3.2 presents data on all cases registered in the
SCCR. This includes cases resident in Switzerland or abroad,
who were diagnosed or treated in Switzerland.
Chapter 3.3 presents data on cases resident in Switzerland, aged 0 to 14 years at diagnosis. This correspondents to
the age group usually covered in international publications.
Therefore, tables and figures can be compared with data from
other countries. Because registration in Switzerland is more
than 95% complete for this age range with estimated incidence and survival rates close to their true value.
Chapter 3.4 presents data on cases resident in Switzerland, aged 15 to 20 years at diagnosis. Patients of this age
group are treated in a large number and variety of clinics and
therefore registration is less complete. Ultimately, incidence
rates cannot be calculated for this age group.
Up to 31st December 2014, a total of 9353 cases classifiable according to the ICCC-3, or Langerhans cell histiocytosis
(LCH), have been registered in the SCCR. These tumours were
diagnosed in 9225 patients. Among these, 9099 patients had
only one primary neoplasm, 124 patients had two primary
neoplasms and 2 patients had three primary neoplasms at age
0 - 20 years.
The SCCR started in 1976. Initially, only patients aged 0
to 15 years who participated in clinical trials were registered.
Non- trial patients have been included since 1982, resulting
in a significant increase in the number registered. In the early
1990s, the introduction of the first electronic database further
increased case registration. Since then, annual registration has
remained constant (Figure 1).
In the last five years (2010 - 2014), a total of 1461 newly
diagnosed cases were registered; among them 1278 cases in
Swiss residents (Table 1).
Swiss residents account for 8317 (89%) of all cases and
foreign residents for 1036 (11%) cases (Table 2). Swiss residents make up 38% (168 /447) of all retinoblastoma patients,
while foreign residents make up 62% (279 /447) of these patients. This is due to the international reputation of the Jules
Gonin Hospital in Lausanne, which is the national centre for
retinoblastoma treatment but also attracts many patients from
abroad.
Figure 1
Annual number of
registered cases over time
Swiss and foreign residents, age
at diagnosis 0 - 14 years; period of
diagnosis 1976 - 2014; all diagnoses
(ICCC - 3 or Langerhans cell
histiocytosis); N = 7504
Annual number of cases
250
200
150
100
50
0
1976
1982
1988
Year of childhood cancer diagnosis
Swiss Childhood Cancer Registry Annual Report 2014/2015
Routine Analyses
1994
2000
2006
2012
Total
Swiss residents
13
Year of diagnosis
All patients
residents
Swiss residents
Foreign
Age at
diagnosis
(years)
Age at
diagnosis
(years)
Age at
diagnosis
(years)
0 - 14
Table 1
Total number of
cases registered in the
SCCR, by period of
diagnosis
15 - 20
0 - 14
15 - 20
0 - 14
15 - 20
1976 - 1984
1151
267
1024
243
127
24
1985 - 1989
864
231
730
213
134
18
1990 - 1994
1080
253
934
231
146
22
1995 - 1999
1043
294
930
268
113
26
2000 - 2004
1072
279
999
257
73
22
2005 - 2009
1061
297
931
279
130
18
2010 - 2014
1233
228
1056
222
177
6
7504
1849
6604
1713
900
136
Swiss and foreign residents, age at diagnosis 0 - 20 years; period of diagnosis 1976 - 2014; all diagnoses (ICCC - 3 or
Langer hans cell histiocytosis); N = 9353
Age at diagnosis (years)
All ages (0 -20)
n
Switzerland
8317
88,9
6604
88,0
1713
92,6
Foreign countries
1036
11,1
900
12,0
136
7,4
726
7,8
645
8,6
81
4,4
• Neighbouring countries
%
n
%
405
4,3
351
4,7
54
2,9
- Austria
10
0,1
10
0,1
0
0,0
- France
141
1,5
110
1,5
31
1,7
79
0,8
74
1,0
5
0,3
174
1,9
156
2,1
18
1,0
1
0,0
1
0,0
0
0,0
- Germany
- Italy
- Liechtenstein
• Other European countries
321
3,4
294
3,9
27
1,5
Middle East
34
0,4
29
0,4
5
0,3
North Africa
152
1,6
122
1,6
30
1,6
48
0,5
41
0,5
7
0,4
Other African countries
Table 2
Total number of cases
registered in the SCCR,
by country of residence
n
Adolescents (15 -20)
Country of residence
Europe
%
Children (0 -14)
All other countries
59
0,6
51
0,7
8
0,4
Abroad
17
0,2
12
0,2
5
0,3
TOTAL
9353
100,0
7504
100,0
1849
100,0
Swiss and foreign residents, age at diagnosis 0 - 20 years; period of diagnosis 1976 - 2013; all diagnoses (ICCC - 3 or
Langerhans cell histiocytosis); N = 9353
14
3.3 Swiss residents aged 0 -14 years
at diagnosis (N = 6604)
ral tissue, nephroblastoma (5%) from renal tissue, hepatoblastoma (1%) in the liver, germ cell tumours (3%), and retinoblastoma (3%).
This chapter reports on cases aged 0 - 14 years and resident in Switzerland at diagnosis with a tumour coded according to ICCC - 3 or a Langerhans cell histiocytosis. Results for
this age group can be compared directly to data from other
countries.
Germ cell tumours may arise in the gonads (ovaries and
testes), or in other sites, such as the brain (intracranial germ
cell tumours). Soft tissue sarcomas (7%), and malignant bone
tumours (4%) arise from abnormal connective tissue. Occasionally, children also develop carcinomas such as melanomas
or other rare tumours (3%). Langerhans cell histiocytosis (3%)
is officially not counted as a malignant disease. But as children
with this disease are treated similarly to those with cancer and
in rare cases also die, they are recorded in the Swiss Childhood
Cancer Registry. The relative frequency of the different tumour
types varies with age (Table 3 and Figure 2).
Diagnoses
The International Classification of Childhood Cancer (ICCC -3)
distinguishes 12 groups of cancers (Table 3). The most common are leukaemias (33% of all cancers), followed by tumours
of the central nervous system (20%; especially brain tumours);
and lymphomas (12%). Other cancers arise from embryonic
tissue. These include neuroblastoma (7%) from primitive neu-
Table 3 Main diagnostic groups according to ICCC - 3, by age at diagnosis
All children
Diagnosis
I
Leukaemias, myeoloproliferative diseases
and myelodysplastic diseases
II
Lymphomas and reticuloendothelial neoplasms
III Central nervous system neoplasms
n
%
n
<1
%
By age at diagnosis (years)
1 -4
5 -9
n
%
n
%
10 - 14
n
%
2167
32,8
87
13,7
1039
45,0
605
34,2
436
23,1
814
12,3
22
3,5
130
5,6
228
12,9
434
23,0
1318
20,0
73
11,5
375
16,2
488
27,6
382
20,2
IV Neuroblastoma and other peripheral
nervous cell tumours
432
6,5
185
29,1
194
8,4
34
1,9
19
1,0
V
167
2,5
78
12,3
80
3,5
8
0,5
1
0,1
339
5,1
48
7,5
196
8,5
83
4,7
12
0,6
Retinoblastoma
VI Renal tumours
VII Hepatic tumours
62
0,9
20
3,1
25
1,1
7
0,4
10
0,5
VIII Malignant bone tumours
285
4,3
0
0,0
19
0,8
86
4,9
180
9,5
IX Soft tissue and other extraosseous sarcomas
443
6,7
47
7,4
127
5,5
111
6,3
158
8,4
179
2,7
36
5,7
42
1,8
25
1,4
76
4,0
184
2,8
4
0,6
8
0,3
40
2,3
132
7,0
X
Germ cell tumours, trophoblastic tumours
and neoplasms of gonads
XI Other malignant epithelial neoplasms
and malignant melanomas
XII Other specified and unspecified malignant neoplasms
Langerhans cell histiocytosis
Total
14
0,2
2
0,3
4
0,2
1
0,1
7
0,4
200
3,0
34
5,3
71
3,1
54
3,1
41
2,2
6604
100,0
636
100,0
2310
100,0
1770
100,0
1888
100,0
Swiss residents; age at diagnosis 0 - 14 years; period of diagnosis 1976 - 2014; all diagnoses (ICCC - 3 or Langerhans cell histiocytosis); N = 6604
Swiss Childhood Cancer Registry Annual Report 2014/2015
Routine Analyses
15
Figure 2
Main diagnostic groups according to ICCC - 3, by age at diagnosis
100%
90%
I.
Leukaemias
II.
Lymphomas
III. CNS neoplasms
80%
IV. Neuroblastoma
70%
V.
Retinoblastoma
VI. Renal tumours
60%
VII. Hepatic tumours
50%
VIII. Malignant bone tumours
IX. Soft tissue sarcomas
40%
X. Germ cell tumours
30%
XI. Other malignant
epithelial neoplasms
20%
XII. Other specified and
unspecified malignant
neoplasms
10%
0%
Langerhans cell histiocytosis
<1
1-4
5-9
Age at diagnosis (years)
10-14
Swiss residents; age at diagnosis 0 - 14 years; period of diagnosis 1976 - 2014; all diagnoses (ICCC - 3 or Langerhans cell histiocytosis);
N = 6604
Follow-up information
The SCCR collects follow- up information for patients in several
ways:
1. Clinical follow- up is any contact the patient has with
the paediatric oncology and haematology centre. Annual
clinical follow- up care in paediatric centres usually ends
5 - 10 years after diagnosis. Then the patient is officially
discharged or referred to an adult oncology centre. Alternatively clinical follow- up also ends as soon as the patient
dies.
2. Long- term epidemiological follow- up for vital status,
subsequent neoplasms and current health employs four
complementary approaches:
• Vital status and current address and place of birth are
updated by contacting municipal population registers.
Vital status is known for most cases: among the 6541
patients, 1636 (25%) have died, and 4905 (75%) are
still alive (Table 4). Among these, most (4608) have been
followed- up during the past 5 years, 165 (3%) have last
been followed up between 2004 and 2008, and only
132 (3%) before 2004. Among the latter, 93 (32 between 2004 - 2008 and 61 before 2004) are lost to follow- up, because they moved abroad.
• Causes of death are retrieved from Swiss mortality statistics by record linkage.
• Second primary neoplasms are notified via paediatric
oncology and haematology centres, detected by regular
comparison with cantonal (regional) cancer registries in
Switzerland, or self- reported by survivors and then validated with pathology reports.
• Morbidity and quality of life are assessed by paper
questionnaires to survivors in the Swiss Childhood Cancer Survivor Study and Childhood Cancer Follow- up
Study (Chapter 4.2).
Table 4
Follow- up information available in the SCCR
n
%
Alive
4905
75.0
Last clinical follow- up after 2008
4608
93.9
Last clinical follow- up 2004 - 2008
165
3.4
Last clinical follow- up before 2004
132
2.7
Deceased
1636
25.0
TOTAL
6541
100.0
Swiss residents; age at diagnosis 0 - 14 years; period of diagnosis 1976 - 2014; all
diagnoses (ICCC - 3 or Langerhans cell histiocytosis); N = 6541 patients (6604 cases)
16
Survival
Long- term survival has improved significantly over the last
decades (Figure 3).
Ten- year survival increased from 58% in children diagnosed between 1976 and 1984, to 71% in children diagnosed
between 1985 and 1994, 80% in children diagnosed between
1995 and 2004, and 87% in children diagnosed within the last
decade (2005 - 2014).
Survival varied widely between diagnostic groups. Figure 4
presents survival by diagnostic group according to ICCC - 3 in
children diagnosed between 1995 and 2014. Of 3916 children, 705 (18%) have died. The following numbers describe
five- year survival for each main diagnostic group: 99% for
Langerhans cell histiocytosis; 96% for germ cell tumours; 95%
for renal tumours; 94% for lymphoma; 94% for retinoblastoma; 85% for children with leukaemia; 83% for malignant bone
tumours; 78% for neuroblastoma; 76% for hepatic tumours;
75% for soft tissue sarcomas and 74% for central nervous system neoplasms.
100%
90%
80%
70%
60%
50%
Figure 3
Survival of patients in the SCCR,
by period of diagnosis
Swiss residents; age at diagnosis 0 - 14 years;
period of diagnosis 1976 - 2014; all diagnoses
(ICCC - 3 or Langerhans cell histiocytosis);
N = 6604; adjusted for age.
40%
Period of diagnosis
30%
2005 - 2014
1995 - 2004
20%
1985 - 1994
10%
1976 - 1984
0%
0
5
10
Years since diagnosis
15
20
25
30
35
40
100%
90%
80%
70%
60%
50%
40%
LHC
Lymphoma
Other malignant tumours
Malignant bone tumours
CNS tumours
30%
Figure 4
Survival of patients by diagnostic
groups according to ICCC - 3
20%
Swiss residents; age at diagnosis 0 - 14 years;
period of diagnosis 1995 - 2014 all diagnoses
(ICCC - 3 or Langerhans cell histiocytosis);
N = 3916; adjusted for age.
0%
10%
0
5
Years since diagnosis
Swiss Childhood Cancer Registry Annual Report 2014/2015
20
Routine Analyses
Retinoblastoma
Renal tumours
Leukemias
Soft-tissue sarcoma
Neuroblastoma
15
20
17
Cancer incidence (2005 -2014) in Switzerland,
for children aged 0 -14 years at diagnosis
Table 5 describes the tumours registered in the SCCR
during the last ten years (2005-2014). Diagnoses are coded
according to ICCC-3, most tumours were more common in
boys than in girls.
The age- standardised incidence (according to the European standard population) of any childhood cancer (not including Langerhans cell histiocytosis) was 16.1 per 100,000
person- years. Incidence was highest among children aged 2
years with 24.9 cases per 100,000 person- years (boys 28.0,
girls 21.6). Incidence was lowest in 9 year olds with 8.6 cases
per 100,000 person- years (boys 9.1, girls 8.0) (Figure 5 shows
crude incidence rates in Swiss residents; age at diagnosis 0 - 14
years; period of diagnosis 1995 - 2014; all diagnoses (ICCC - 3
but not including Langerhans cell histiocytosis); Figure 6 shows
age- and sex- specific incidence rates for age 0 - 14).
Table 5
Childhood cancer diagnosed in Switzerland 2005 - 2014: number of cases, relative frequency, sex ratio, median age at diagnosis and
incidence standardised according to the European standard population, by diagnostic groups according to ICCC - 3
n
Relative
frequency
Leukaemias, myeloproliferative diseases and myelodysplastic diseases
648
33,6
1,6
4,8
5,4
a. Lymphoid leukaemias
522
80,6
1,5
4,7
4,4
78
12,0
1,9
4,7
0,7
9
1,4
3,5
10,0
0,1
32
4,9
3,0
6,3
0,3
7
1,1
0,8
5,5
0,1
215
11,2
1,8
10,9
1,8
96
44,7
0,9
12,7
0,8
Diagnosis
I
b. Acute myeloid leukaemias
c. Chronic myeloproliferative diseases
d. Myelodysplastic syndrome and other myeloproliferative diseases
e. Unspecified and other specified leukaemias
II
Lymphomas and reticuloendothelial neoplasms
a. Hodgkin lymphomas
b. Non- Hodgkin lymphomas (except Burkitt lymphoma)
58
27,0
2,9
8,9
0,5
c. Burkitt lymphoma
56
26,0
7,0
7,3
0,5
d. Miscellaneous lymphoreticular neoplasms
5
2,3
0,3
1,3
0,0
e. Unspecified lymphomas
0
NA
NA
NA
NA
442
22,9
1,2
6,8
3,7
48
10,9
1,3
2,7
0,4
186
42,1
1,1
7,0
1,6
80
18,1
1,4
6,5
0,7
III CNS and miscellaneous intracranial and intraspinal neoplasms
a. Ependymomas and choroid plexus tumour
b. Astrocytomas
c. Intracranial and intraspinal embryonal tumours
d. Other gliomas
52
11,8
1,3
6,5
0,4
e. Other specified intracranial and intraspinal neoplasms
67
15,2
1,2
10,8
0,6
f. Unspecified intracranial and intraspinal neoplasms
IV Neuroblastoma and other peripheral nervous cell tumours
a. Neuroblastoma and ganglioneuroblastoma
b. Other peripheral nervous cell tumours
V
Retinoblastoma
VI Renal tumours
a. Nephroblastoma and other nonepithelial renal tumours
b. Renal carcinomas
c. Unspecified malignant renal tumours
VII Hepatic tumours
a. Hepatoblastoma
18
Sex ratio
Age at Dx
(male:female) (Median) Incidence*
9
2,0
0,8
8,6
0,1
118
6,1
1,1
1,5
1,0
118
100,0
1,1
1,5
1,0
0
NA
NA
NA
NA
42
2,2
0,8
1,0
0,4
98
5,1
0,8
3,3
0,8
93
94,9
0,8
3,2
0,8
5
5,1
0,7
12,8
0,0
0
NA
NA
NA
NA
15
0,8
2,0
2,1
0,1
14
93,3
1,8
1,9
0,1
b. Hepatic carcinomas
1
6,7
0,0
14,1
0,0
c. Unspecified malignant hepatic tumours
0
NA
NA
NA
NA
Table 5 Continued
Diagnosis
VIII Malignant bone tumours
a. Osteosarcomas
b. Chondrosarcomas
c. Ewing tumour and related sarcomas of bone
Sex ratio
Age at Dx
(male:female) (Median) Incidence*
79
4,1
0,9
11,2
0,7
38
48,1
0,9
11,7
0,3
1
1,3
0,0
14,4
0,0
39
49,4
1,0
10,9
0,3
d. Other specified malignant bone tumours
0
NA
NA
NA
NA
e. Unspecified malignant bone tumours
1
1,3
0,0
14,7
0,0
139
7,2
1,4
7,8
1,2
78
56,1
1,4
5,5
0,7
b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms 10
7,2
2,3
10,9
0,1
c. Kaposi sarcoma
0
NA
NA
NA
NA
d. Other specified soft tissue sarcomas
40
28,8
0,9
11,1
0,3
e. Unspecified soft tissue sarcomas
11
7,9
4,5
2,8
0,1
Germ cell tumours, trophoblastic tumours, and neoplasms of gonads
58
3,0
1,1
6,4
0,5
a. Intracranial and intraspinal germ cell tumours
15
25,9
2,0
12,1
0,1
IX Soft tissue and other extraosseous sarcomas
a. Rhabdomyosarcomas
X
Relative
frequency
n
b. Malignant extracranial and extragonadal germ cell tumours
18
31,0
0,6
0,2
0,2
c. Malignant gonadal germ cell tumours
24
41,4
1,2
11,5
0,2
d. Gonadal carcinomas
0
NA
NA
NA
NA
e. Other and unspecified malignant gonadal tumour
1
1,7
0,0
0,8
0,0
71
3,7
0,6
12,2
0,6
2
2,8
1,0
6,4
0,0
14
19,7
0,3
13,5
0,1
2
2,8
1,0
13,6
0,0
15
21,1
0,5
10,4
0,1
7
9,9
1,3
7,0
0,1
31
43,7
0,6
12,0
0,3
3
0,2
2,0
0,0
0,0
a. Other specified malignant tumours
2
66,7
1,0
1,8
0,0
b. Other unspecified malignant tumours
1
33,3
0,0
0,0
0,0
1928
100,0
1,3
6,2
16,1
59
3,0
1,4
5,2
0,5
1987
100,0
1,3
6,2
16,6
XI Other malignant epithelial neoplasms and malignant melanomas
a. Adrenocortical carcinomas
b. Thyroid carcinomas
c. Nasopharyngeal carcinomas
d. Malignant melanomas
e. Skin carcinomas
f. Other and unspecified carcinoma
XII Other and unspecified malignant neoplasms
Total (not including Langerhans cell histiocytosis)
Langerhans cell histiocytosis
Total (including Langerhans cell histiocytosis)
* Incidence: newly diagnosed tumours in a one year time period per 100,000 persons (person - years)
Swiss residents; age at diagnosis 0 - 14 years, period of diagnosis 2005 - 2014, all diagnoses (ICCC - 3 or Langerhans cell histiocytosis); N = 1987
Swiss Childhood Cancer Registry Annual Report 2014/2015
Routine Analyses
19
20.0
Figure 5
Crude incidence rate (per 100,000
person - years) in Switzerland, by sex
and year of diagnosis for the last
20 years (1995 - 2014)
Incidence rate
15.0
10.0
Total
Boys
Girls
5.0
Swiss residents; age at diagnosis 0 - 14 years;
period of diagnosis 1995 - 2014; all diagnoses
(ICCC - 3 but not including Langerhans cell
histiocytosis); N = 3916
0.0
2000
1995
Year of childhood cancer diagnosis
2005
2010
2014
30
Boys
Girls
25
20
15
10
Figure 6
Age- and sex- specific incidence
rates (per 100,000 person- years) in
Switzerland for the last 10 years
Swiss residents; age at diagnosis 0 - 14 years;
period of diagnosis 2005 - 2014; all diagnoses
(ICCC - 3 but not including Langerhans
cell histiocytosis); N = 1928
20
5
0
1
2
3
0
Age at diagnosis
4
5
6
7
8
9
10
11
12
13
14
3.4 Swiss residents aged 15 -20 years
at diagnosis (N = 501)
Table 6 describes the tumours registered in the last ten
years (2005 - 2014) diagnosed in adolescent patients (aged
15 - 20 years at diagnosis, N = 501). Because data on adolescents are currently not complete within the SCCR, we do not
present incidence rates. In adolescents the sex ratio is closer to
1 than in those aged 0 - 14 years at diagnosis.
Table 6
Adolescent cancer diagnosed in Switzerland 2005 - 2014: number of cases, relative frequency, sex ratio, median age at diagnosis
I
Diagnosis
n
Relative
frequency
Sex ratio
(male:female)
Age at Dx
(Median)
Leukaemias, myeloproliferative diseases and myelodysplastic diseases
61
12,2
1,4
16,4
a. Lymphoid leukaemias
31
50,8
2,1
15,9
b. Acute myeloid leukaemias
16
26,2
0,8
16,8
c. Chronic myeloproliferative diseases
8
13,1
1,0
18,1
d. Myelodysplastic syndrome and other myeloproliferative diseases
6
9,8
2,0
16,7
e. Unspecified and other specified leukaemias
II
0
NA
NA
NA
131
26,3
0,8
16,7
a. Hodgkin lymphomas
93
71,0
0,8
16,7
b. Non - Hodgkin lymphomas (except Burkitt lymphoma)
32
24,4
1,0
17,0
c. Burkitt lymphoma
5
3,8
1,5
17,9
d. Miscellaneous lymphoreticular neoplasms
1
0,8
0,0
16,6
Lymphomas and reticuloendothelial neoplasms
e. Unspecified lymphomas
III CNS and miscellaneous intracranial and intraspinal neoplasms
a. Ependymomas and choroid plexus tumour
b. Astrocytomas
NA
NA
NA
16,8
1,2
16,7
6
7,1
1,0
18,3
26
31,0
0,7
16,7
c. Intracranial and intraspinal embryonal tumours
16
19,0
1,7
16,5
d. Other gliomas
10
11,9
1,0
16,8
e. Other specified intracranial and intraspinal neoplasms
25
29,8
1,5
16,5
1
1,2
0,0
15,4
0
NA
NA
NA
0
NA
NA
NA
f. Unspecified intracranial and intraspinal neoplasms
IV Neuroblastoma and other peripheral nervous cell tumours
a. Neuroblastoma and ganglioneuroblastoma
V
0
84
b. Other peripheral nervous cell tumours
0
NA
NA
NA
Retinoblastoma
0
NA
NA
NA
VI Renal tumours
7
1,4
2,5
16,6
a. Nephroblastoma and other nonepithelial renal tumours
2
28,6
0,0
16,0
b. Renal carcinomas
5
71,4
1,5
17,4
c. Unspecified malignant renal tumours
0
NA
NA
NA
VII Hepatic tumours
2
0,4
0,0
17,4
a. Hepatoblastoma
0
NA
NA
NA
b. Hepatic carcinomas
2
100,0
0,0
17,4
c. Unspecified malignant hepatic tumours
0
NA
NA
NA
48
9,6
1,5
16,2
33
68,8
1,8
16,3
VIII Malignant bone tumours
a. Osteosarcomas
b. Chondrosarcomas
1
2,1
0,0
15,1
12
25,0
1,0
16,0
d. Other specified malignant bone tumours
2
4,2
1,0
16,7
e. Unspecified malignant bone tumours
0
NA
NA
NA
c. Ewing tumour and related sarcomas of bone
Swiss Childhood Cancer Registry Annual Report 2014/2015
Routine Analyses
21
Table 6 Continued
Diagnosis
IX Soft tissue and other extraosseous sarcomas
a. Rhabdomyosarcomas
b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms
c. Kaposi sarcoma
d. Other specified soft tissue sarcomas
e. Unspecified soft tissue sarcomas
X
n
Relative
frequency
Sex ratio
(male:female)
Age at Dx
(Median)
33
6,6
0,9
16,7
13
39,4
0,9
16,1
3
9,1
0,0
15,8
0
NA
NA
NA
13
39,4
0,4
17,4
4
12,1
3,0
16,8
38
7,6
8,5
17,8
a. Intracranial and intraspinal germ cell tumours
3
7,9
0,0
17,2
b. Malignant extracranial and extragonadal germ cell tumours
0
NA
NA
NA
33
86,8
15,5
18,0
2
5,3
0,0
15,7
Germ cell tumours, trophoblastic tumours, and neoplasms of gonads
c. Malignant gonadal germ cell tumours
d. Gonadal carcinomas
e. Other and unspecified malignant gonadal tumour
XI Other malignant epithelial neoplasms and malignant melanomas
a. Adrenocortical carcinomas
b. Thyroid carcinomas
c. Nasopharyngeal carcinomas
d. Malignant melanomas
e. Skin carcinomas
f. Other and unspecified carcinoma
XII Other and unspecified malignant neoplasms
a. Other specified malignant tumours
b. Other unspecified malignant tumours
Total (not including Langerhans cell histiocytosis)
Langerhans cell histiocytosis
Total (including Langerhans cell histiocytosis)
0
0,0
NA
NA
93
18,6
0,7
18,1
1
1,1
0,0
17,0
25
26,9
0,1
18,0
3
3,2
2,0
18,7
29
31,2
0,9
18,6
9
9,7
0,8
18,4
26
28,0
1,4
17,7
2
0,4
0,0
16,3
2
100,0
0,0
16,3
0
NA
NA
NA
499
100,0
1,1
16,8
2
0,4
1,0
16,4
501
100,0
1,1
16,8
Age at diagnosis 15 - 20 years, period of diagnosis 2005 - 2014, all diagnoses (ICCC - 3 or Langerhans cell histiocytosis); N = 501
22
4. Research on childhood cancer
The research of the childhood cancer registry focusses on
three main topics: Aetiology of childhood cancer, long- term
outcomes, and follow -up care after childhood cancer or young
adult cancer. These topics are described with their background,
aims, methods, recent findings, ongoing studies, and contacts
in the remainder of Chapter 4. Additional information is avail-
able from the investigators and our website (www.childhoodcancerregistry.ch). Further, we thank the supporters for their
generous contributions towards the research projects.
All ongoing studies, their funding sources and the senior
investigator are summarized in Table 7.
Table 7
Research grants of the SCCR, summary
No Project name
Senior investigator
Funding sources
Study period
1 Spatial and spatio - temporal clustering of childhood
cancer: The role of infections and environmental hazards
Spycher BD
Swiss Cancer Research
(KFS - 3515 - 08 - 2014)
01.2014 - 12.2016
2 The spatial epidemiology of childhood cancer in Switzerland
Spycher BD
Swiss National Science
Foundation (PZ00P3_147987)
09.2013 - 08.2016
3 The role of population mixing and exposure to infections in
Spycher BD
the aetiology of childhood leukaemia: A national cohort study
Swiss Cancer Research
(KFS - 3049 - 08 - 2012)
01.2013 - 12.2014
4 Childhood cancer and geographically defined exposures
in Switzerland: A census - based nationwide cohort study
Federal Office of Public Health
(12.008357)
03.2013 - 11.2013
5 Childhood cancer and vicinity of residence to petrol stations Kuehni CE
and roads: A census -based nationwide cohort study (PETROL)
Federal Office of Public Health
(10.002946)
06.2010 - 02.2013
6 Childhood cancer and nuclear power plants in Switzerland:
A census - based cohort study
Swiss Cancer League
(02224 - 03 - 2008);
Federal Office of Public Health
(08.001616)
09.2008 - 02.2011
Kuehni CE, Angst R
Kuehni CE,
Bergstraesser E
Kuehni CE
Von der Weid NX,
Kuehni CE
Von der Weid NX,
Kuehni CE
Kuehni CE
Cancer League Aarau
Cancer League Zurich
01.2012 - 12.2012
08.2010 - 07.2011
Cancer League Bern
Swiss Cancer League
(KLS - 2215 - 02 - 2008)
Swiss Cancer League
(KLS - 1605 - 10 - 2004)
Kinderkrebshilfe Schweiz
04.2009 - 03.2010
07.2008 - 06.2010
Kuehni CE
Swiss Cancer League
(KLS - 3412 - 02 - 2014)
EU (FP7 - HEALTH - F2 - 2013 602030; project no. 602030)
07.2014 - 06.2017
Aetiology of childhood cancer
Spycher BD
Kuehni CE
Outcome research (Long - term outcomes, follow - up care, international collaboration)
1 Swiss Childhood Cancer Survivor Study (SCCSS)
2 PanCare Studies in Fertility and Ototoxicity to improve
Quality of Life after Cancer during Childhood,
Adolescence and Young Adulthood (PanCareLIFE)
Kuehni CE
01.2006 - 10.2008
since 2006
11.2013 - 10.2018
3 Dietary habits, nutrition and risk of late effects
after childhood cancer
Bochud M, Kuehni CE
Swiss Cancer League
(KLS - 3644 - 02 - 2015)
07.2015 - 06.2018
4 Psychological late effects in long - term childhood cancer
survivors – Development of guidelines for follow - up care
Michel G
Krebsliga Zentralschweiz
11.2015 - 10.2017
5 PanCare childhood and adolescent cancer survivor care
and follow - up studies (PanCareSurFup)
Kuehni CE
Swiss Cancer Research
(KFS - 02783 - 02 - 2011)
EU (FP7 - HEALTH - F2 - 2010 257505; project no. 257505)
08.2011 - 07.2014
Kuehni CE
6 Mortality after cancer in childhood and adolescence
Kuehni CE
Kuehni CE
02.2011 - 01.2017
Swiss National Science
08.2012 - 08.2015
Foundation (PDFMP3_141775)
Swiss Bridge
7 Follow - up care after childhood and young adult
cancer (CCFU)
Michel G
Swiss National Science
Foundation (PZ00P3_121682
and PZ00P3_141722)
08.2009 - 08.2014
8 Effectiveness of transition from paediatric to adult
care after childhood cancer
Michel G
Swiss Cancer League
(KFS - 02631 - 08 - 2010)
04.2011 - 04.2014
Research projects on childhood cancer
23
Swiss Childhood Cancer Registry Annual Report 2014/2015
No Project name (continued)
Senior investigator
Funding sources
9 Parents of long-term childhood cancer survivors
Michel G
Swiss National Science
Foundation
(100019_153268 /1)
Kinderkrebshilfe Schweiz
since 2013
10 Fertility after Chemo- and Radiotherapy in Childhood
and Adolescence, FeCt – Multicentre
Michel G
Kinderkrebshilfe Schweiz
since 2012
11 Risk of cancer and long-term mortality in children
treated with growth hormone:
Swiss participation in the EU FP7 project (SAGhE)
Mullis P, Kuehni CE
Swiss Cancer League
(KLS-2948-02-2012)
EU (FP-HEALTH-F2-2009223497)
Swiss Cancer League
(KLS-02586-02-2010)
07.2012-12.2013
Mullis P
Mullis P, Kuehni CE
24
Study period
04.2011-03.2014
07.2010-12.2012
4.1 Aetiology of childhood cancer
Background
The aetiology of childhood cancers remains largely unknown. For leukaemia, the most frequent childhood cancer,
known risk factors include trisomy 21, certain rare genetic
syndromes, some common germline genetic variants, high
birthweight, and high parental age at birth. Regarding environmental exposures, only ionising radiation at medium to
high doses is an established risk factor – both for leukaemia
and CNS tumours. Numerous other environmental factors are
being discussed as potential risk factors. These include: low
dose ionising radiation (e.g. natural background radiation and
diagnostic radiation), traffic related air pollution, electromagnetic fields (e.g. from power lines, radio and TV transmitters,
or mobile phones) pesticides, and infections.
Aims
The broad aims of the research group are to investigate
whether:
• Cancer risks in children are associated with environmental exposures, such as ionising and non- ionising radiation, air pollution and exposure to infectious diseases, as
well as parents workplace exposures;
• Cancer risks in children are associated with socio economic, family or perinatal exposures;
• Cases of cancer tend to cluster in space and /or in space
and time and, if yes, to elicit aetiological clues from the
pattern of clustering.
Methods
Clinical and residential information on diagnosed cases
are obtained from the SCCR. Data on the population at risk
are obtained from the Swiss National Cohort (SNC) which
includes the entire Swiss resident population at census time
points (1990, 2000, and annually from 2010 onward). Record
linkage between the two datasets allows investigating cancer
incidence on a nationwide scale with a cohort design. The
SCCR collects geocoded address histories from birth to diagnosis allowing to distinguish different exposure time windows.
Geocoded places of residence are also available for the entire
population from the SNC. This allows calculating geographically determined exposures such as distance to highways or NO2
concentration levels (based on spatial pollution models) for the
entire population at risk. The SNC also provides demographic,
socioeconomic and perinatal data for the entire population.
The availability of precise geocodes of residence allows assessing spatial and spatio- temporal clustering using methods for
point pattern data rather than methods for less precise regional count data (e.g. aggregated at municipality level).
Swiss Childhood Cancer Registry Annual Report 2014/2015
Current status
A, Recent findings: A summary of our recent research
and findings is given in [Lupatsch - 2016a]. We found evidence of increased risks of childhood leukaemia and CNS
tumours among children exposed to higher levels of natural
background radiation (terrestrial gamma and cosmic radiation) [Spycher - 2015a, 2015b, 2015c]. Young children living
in the immediate proximity (<100m) of highways were found
to have an increased leukaemia risk [Spycher - 2015d]. We
found little evidence of associations between childhood leukaemia and commonly used measures of population mixing
[Lupatsch - 2015b, c] or for associations between leukaemia
risk and socioeconomic status [Adam - 2015]. However, we did
find evidence of a temporal association between childhood
leukaemia and periods of rapid population growth in Swiss
municipalities [Lupatsch - 2016d]. We found evidence for spatio- temporal clustering of leukaemia around the time of birth,
but not around the time of diagnosis [Kreis - 2016].
B, Ongoing studies: In ongoing studies we are investigating whether: i) Childhood cancer is associated with increased
air concentrations of benzene and NO2; ii) Childhood leukaemia is associated with perinatal characteristics (including parental age, birth order, age difference to next older sibling, and
birth weight); iii) Cases of childhood leukaemia born close in
time and space to another case (clustered cases) differ from
non- clustered cases with respect to diagnostic, socio economic
characteristics and environmental exposures; and iv) whether
there is evidence for spatial clustering in Switzerland. Furthermore, we are v) collaborating in an international case control
study on the association between childhood cancer and proximity to power lines.
Contact
The research team consists of Ben Spycher, Claudia Kuehni,
Christian Kreis and Garyfallos Konstantinoudis.
Research projects on childhood cancer
25
4.2 Long-term outcomes
Background
Cancer is the most common disease-related cause of death
during childhood in the Western world. Thanks to therapeutic
improvements in the recent decades, survival rates for childhood
cancer now exceed 80%, leading to a growing population of
long- term survivors. However, cancer and its treatment can
cause adverse late effects, such as second primary malignancies, cardiovascular disease, hearing loss and infertility. These
adverse late effects may affect survivors’ health, health behaviour and quality of life, and may lead to premature death.
Comprehensive data on the burden of late effects of childhood
cancer including premature mortality and their risk factors are
scarce. The SCCR has a broad research program focusing on
long- term outcomes that includes the national Swiss Childhood Cancer Survivor Study (SCCSS) and a study on cause- specific long- term mortality.
Aims
The research group aims:
• To investigate prevalence, incidence and spectrum of
somatic and psychosocial outcomes including second
primary neoplasms, somatic health, mental health,
educational and social outcomes, health- related quality
of life, and cause- specific long- term mortality.
• To determine sociodemographic, cancer- and treatment
related predictors associated with long- term outcomes.
• To describe health behaviours in long- term survivors.
Methods
This prospective cohort study is based on children and adolescents registered in the SCCR.
Study population: All individuals who are at least 5-year survivors, who were diagnosed with cancer at age < 21 years, and
were Swiss residents at time of diagnosis are eligible.
Collected data: A detailed questionnaire is sent to childhood cancer survivors and their parents to obtain data about
somatic, psychosocial, and mental health outcomes. For comparison, a similar questionnaire is sent to siblings of survivors.
Questionnaire data are complemented with phone interviews
to patients and are validated with information from general
practitioners and hospital records, e.g. audiometric or lung
function tests to validate hearing problems or lung diseases.
Furthermore, we collect data from municipal population registries to obtain vital statistics including dates of death, and
Swiss mortality statistics to obtain causes of death. For some
studies, we also collect saliva samples for genetic analyses.
These broad data make it possible to investigate prevalence
and incidence of adverse late effects and to identify their predictors in Swiss survivors.
Response rate: For the SCCSS questionnaire survey, we
contacted 2930 five- years survivors aged 0 to 16 years at diagnosis, 2235 (76%) completed our questionnaire. Among 598
contacted survivors aged 16 - 20 years at diagnosis whom we
contacted, 320 (57%) participated. We also contacted 1522
siblings, of whom 866 (57%) participated.
26
Current status
A, Recent findings
This study offers the first national-level data on adverse
late effects, health behaviour, survival and long-term mortality
after cancer in childhood and adolescence in Switzerland. The
study is ongoing and we are currently contacting new 5 - year
survivors diagnosed between 2005 - 2010. We obtained causes
of death of 3965 of the 5 - year survivors who subsequently
died. We analyse and publish our findings continuously. Previous publications have included topics like health-related quality of life, education, cognitive problems, partnership, income,
physical activity, nutrition, survival, and mortality. Our findings
will help to identify patients who are at increased risk for late
effects, to adjust therapies and to develop tailored follow- up
programs for survivors.
Health- related quality of life (HRQoL): We found that the
overall HRQoL of young survivors (8 - 16 years) was comparable
to population norms for most parent- reported dimensions and
higher for most self- reported dimensions [Wengenroth - 2015].
However, older survivors (>16 years) had lower HRQoL than
their siblings, and among survivors, those with chronic health
problems had the lowest health- related quality of life [Rueegg2013]. Survivors of acute lymphoblastic leukemia reported
good HRQoL, even after a relapse [Essig - 2012].
Educational and social outcomes: We also showed that
survivors achieved educational levels similar to the general
population [Kuehni - 2012]. Survivors younger than 20 years
were more likely than their siblings to report cognitive problems [Wengenroth - 2015]. We found lower personal income
in survivors than in siblings [Wengenroth - 2016]. However, survivors’ personal income may increase later because treatment
can push back education and carreer training and cause survivors to start working later than their peers. Survivors are less
likely than peers to be married or in a life partnership [Wengenroth - 2014]. This might be because survivors take longer to
reach their final educational achievement, which might in turn
encourage them to delay marriage.
Physical activity: We found that daily physical activity
and sport levels in survivors were similar to the general population. Physical activity was mainly determined by socio- demographic and cultural factors [Rueegg - 2012a]. However,
we found that survivors are at high risk of suffering from performance limitations in sports and in daily living activities and
that these limitations differed strongly between diagnostic
groups [Rueegg - 2012b]. Despite these physical performance
limitations, many survivors maintained healthy activity levels
[Rueegg -2013].
Nutrition: We showed that the adherence to dietary recommendations among survivors was similar to their siblings
and the general population, but poor overall [Belle - submitted].
Hearing loss: We found that the burden of hearing loss
as a late effect after ototoxic cancer treatment has stabilized in
recently treated survivors, which suggests that survivors have
benefited from new treatment regimens that use less ototoxic
radiation and more carefully dosed platinum compounds [Weiss
- accepted].
Mortality: We found that the mortality of five- year survivors of childhood cancers is elevated compared to the general
population, with recurrence and progression of the original
cancer as the most common causes of death up to 24 years
after diagnosis [Schindler - 2016].
B, Ongoing studies
Ongoing studies focus on different somatic health problems and health behaviours:
i) diseases; ii) cardiac diseases; iii) hearing loss; and iv) dietary habits and excess weight. We are also collaborating with
international studies (see International collaborations).
Contact
The research team consists of Claudia Kuehni, Fabiën Belle,
Rahel Kasteler, Rahel Kuonen, Matthias Schindler, Grit Sommer,
Annette Weiss, Gisela Michel and Nicolas von der Weid.
Swiss Childhood Cancer Registry Annual Report 2014/2015
Research projects on childhood cancer
27
4.3 International collaborations
Background
Late effects of childhood cancer and its treatment are
common, but numbers in individual countries are low. Therefore, pooling of data into large international cohorts is essential to identify risk factors for late effects using observational
data and genetic tools. Survivors can benefit from personalized, evidence- based care based on their individual risk; and
future patients may benefit from adapted treatment, that
cause less severe side effects.
International studies on childhood cancer often also include systematic reviews that summarize the evidence on risk
factors of late effects. These provide the basis for creating new
guidelines for the clinical long- term follow- up of survivors of
cancer diagnosed at a young age.
The SCCR collaborates with other childhood cancer cohorts [Bhatia - 2015, Winther - 2015], participates in European
studies to investigate late effects, and is involved in the development of international guidelines for clinical long- term follow- up of childhood and adolescent cancer survivors.
Aims
Within the international collaborations, we aim to investigate:
• Prevalence and incidence of late effects of childhood and
adolescent cancer and its treatment
• Risk factors for these late effects
We also aim to develop guidelines to improve the health
and quality of life of current and future survivors of childhood
cancer.
Methods
Swiss patients of childhood and adolescence cancer are
part of a Pan- European cohort. Researchers within this European collaboration can then select patients with late effects,
for example patients with a second primary cancer, cardiac or
hearing problems, for nested case- control or case- cohort studies. Within these studies, researchers can identify non- genetic
and genetic risk factors of late effects.
Experts and the International Guideline Harmonization
Group (IGHG, http: / /www.ighg.org /) write up systematic reviews to develop evidence- based, standardised guidelines for
clinical follow- up of survivors.
28
Current status
A, Ongoing studies:
Swiss patients of childhood and adolescence cancer are
part of Pan- European cohorts. Researchers within this European collaboration can then select patients with late effects,
for example patients with a second primary cancer, cardiac or
hearing problems, for nested case- control or case- cohort studies. Within these studies, researchers can identify non- genetic
and genetic risk factors of late effects. Currently, we are collaborating in two ongoing studies:
PanCareSurFup (PanCare childhood and adolescent cancer survivor care and follow- up studies; http: / /www.pancaresurfup.eu /)
This project investigates the burden and risk factors of
the most severe and life threatening late effects, namely second primary neoplasms, cardiovascular disease and premature
death. We contributed with 4719 Swiss 5 - year survivors to the
Pan- European cohort and with detailed treatment data from
medical records of 139 Swiss survivors to the European nestedcase control studies.
Recent findings: A new method to facilitate valid and
consistent grading of cardiac events in childhood cancer survivors has been published [Feijen - 2014] and several other publications are in preparation.
PanCareLIFE (PanCare Studies in Fertility and Ototoxicity
to Improve Quality of Life after Cancer during Childhood, Adolescence and Young Adulthood; http: / /www.pancarelife.eu /)
This project investigates hearing loss, infertility and quality
of life. We identified survivors at risk for hearing loss and collected their audiograms. We will contribute questionnaire data
on hearing loss, fertility and quality of life from the SCCSS. We
will be responsible, together with the University of Münster in
Germany, for the statistical analysis of quality of life data from
eight European countries.
B, Development of guidelines
In close collaboration with European and American experts and the International Guideline Harmonization Group
(IGHG, http: / /www.ighg.org /), we write systematic reviews
do develop evidence- based, standardized guidelines for clinical follow- up of survivors. We are currently involved as chairs,
work group (WG) leaders and group members in the development of the following guidelines:
Hearing loss (ototoxicity)
• Chairs: Wendy Landier (USA), Richard Cohn (AUS)
• WG leaders: Claudia Kuehni (CH), Thorsten Langer (DE)
l Pulmonary dysfunction
• Chairs and WG leaders: Claudia Kuehni (CH),
Andrew Dietz (USA)
l Fatigue, mental health and psychosocial problems
• Chairs: Gisela Michel (CH),
Jordan Gilleland Marchak (USA)
• Fatigue WG leaders: Kathrin Scheinemann (CH),
Gisela Michel (CH)
• Mental Health WG leaders: Janine Vetsch (CH),
Jordan Gilleland Marchak (USA)
l
Once the guidelines will be available, all centres of the
Swiss Paediatric Oncology Group will implement these guidelines in Switzerland.
Recent findings: A survey among paediatric oncology /haematology clinics from 44 European countries found
that many clinics have insufficient or lack programmes for
long- term follow- up into adulthood for survivors of childhood
cancer [Brown - 2015]. This study showed that available guidelines are not universally used throughout Europe and we need
to further develop and disseminate Pan- European long- term
follow- up guidelines.
Contact
The research team consists of Claudia Kuehni, Rahel Kasteler, Rahel Kuonen, Grit Sommer, Annette Weiss, Gisela Michel
and Nicolas von der Weid.
Swiss Childhood Cancer Registry Annual Report 2014/2015
Research projects on childhood cancer
29
4.4 Psychosocial outcomes and follow-up care
Background
Treatment for cancer in children and young adults has
greatly improved and most patients can be cured today. However, more than 50% of survivors of childhood cancer suffer
from late effects. Similarly, parents might suffer long after their
child has been cured. To detect and treat late effects as early as
possible, most survivors should continue to attend follow- up
care long after their cancer has been cured. Follow- up care
needs to be constantly updated to meet the current status of
research. International guidelines summarising the care needed after different cancers and treatment are necessary. Additionally, while various models of follow- up care have been
described, so far none has been implemented in Switzerland.
A successful model must not only take clinical aspect into account but also survivors’ preferences and needs.
Aims
The research group aims to:
• Describe follow- up care models available across Europe,
and preferences for a follow- up model among Swiss
childhood and young adult cancer survivors, parents and
physicians (oncologists and general practitioners)
• Evaluate the transition / transfer from paediatric to adult
care in survivors of childhood cancer
• Describe psychological and socio- demographic outcomes, as well as needs in parents of long- term childhood cancer survivors
Methods
To describe follow- up care models in Europe, we invited
198 clinics and follow- up programmes in Europe to complete
a questionnaire survey describing the follow- up care available
at their institution. To assess preferences for different models
of follow- up care, a questionnaire survey assessed opinions
and perspectives on both currently used and desired optimal follow- up care among survivors, parents, paediatric and
adult oncologists / haematologists and family practitioners.
We evaluated the transition from paediatric to adults among
childhood cancer survivors using medical records. Finally, we
will contact parents in a questionnaire survey to assess positive and negative psychological, familial, and social outcomes
[Mader - 2016]. These outcomes will be compared to the Swiss
general population.
30
Current status
A, Recent Findings:
Follow- up care: Our survey among European paediatric
oncology /haematology clinics found that many still lacked programmes for long- term follow- up into adulthood [Essig - 2012,
Brown - 2015]. Additionally, a large proportion of Swiss survivors do not attend regular follow- up care [Michel - 2011,
Rebholz - 2011, Lupatsch - 2016e]. Survivors and their parents
desire precise information on late effects and follow- up care
[Gianinazzi - 2014a, Vetsch - 2015]. Most survivors and parents reported preferences for care by a specialist (oncologist)
[Vetsch - 2016, Christen - 2016].
Psychological late effects: We found that survivors are at increased risk for psychological distress [Michel - 2010, Gianinazzi 2013, Gianinazzi - 2014b, Michel - 2015, Gianinazzi - 2016] or
other negative psychosocial outcomes [Wengenroth - 2014,
2015a, 2015b, Kuehni - 2012a, Rebholz - 2012].
Transition: In Switzerland, there is no specialised transition programme for survivors of childhood cancer from paediatric to adult care. We investigated if patients are receiving
e.g. follow- up information after release from the paediatric
oncology clinic [Gianinazzi - 2015]. Patient- adapted information on diagnosis, treatment and future follow- up, provided at
the time of discharge, was rarely found.
B, Ongoing studies:
The study on parents of childhood cancer survivors will be
the first population- based study among parents of long- term
survivors of childhood cancer and will shed light on their psychological well- being, social outcomes and the needs they
have for their children and themselves.
Contact
The research team consists of Gisela Michel, Katharina
Roser, Luzius Mader, Julia Bänziger, Janine Vetsch, Salome
Christen, Claudia Kuehni, and Nicolas von der Weid.
5. Publications of the Swiss Childhood Cancer Registry
All articles published using SCCR data from January 2007
– June 2016 are reported below. Additional publications related to the SCCR or SPOG can be found on the SCCR and SPOG
websites: www.childhoodcancerregistry.ch and www.spog.ch.
5.1 Original articles (Peer reviewed journals)
2016
1. Adam M, Rueegg CS, Schmidlin K, Spoerri A, Niggli F, Grotzer
M, von der Weid NX, Egger M, Probst -Hensch N, Zwahlen
M, Kuehni CE. Socioeconomic disparities in childhood cancer
survival in Switzerland. Int J Cancer. 2016; 138(12):2856 -66.
2. Christen S, Vetsch J, Mader L, Dehler S, Korol D, Kuehni CE,
Rueegg CS, Michel G. Preferences for the organization of
long -term follow -up in adolescent and young adult cancer
survivors. Support Care Cancer. 2016; 24(8):3425 -36.
3. Essig S, Steiner C, Kuehni CE, Weber H, Kiss A. Improving
Communication in Adolescent Cancer Care: A Multiperspective Study. Pediatr Blood Cancer. 2016; 63(8):1423 -30.
4. Gianinazzi ME, Rueegg CS, Vetsch J, Luer S, Kuehni CE, Michel G, Swiss Pediatric Oncology G. Cancer’s positive flip
side: posttraumatic growth after childhood cancer. Support
Care Cancer. 2016; 24(1):195 -203.
5. Kreis C, Grotzer M, Hengartner H, Daniel Spycher B, Swiss
Paediatric Oncology G, the Swiss National Cohort Study G.
Space -time clustering of childhood cancers in Switzerland: A
nationwide study. Int J Cancer. 2016; 138(9):2127 -35.
6. Lupatsch JE, Kreis C, Zwahlen M, Niggli F, Ammann RA,
Kuehni CE, Spycher BD, Swiss Paediatric Oncology G, Swiss
National Cohort Study G. Temporal association between
childhood leukaemia and population growth in Swiss municipalities. Eur J Epidemiol. 2016d.
7. Lupatsch JE, Wengenroth L, Rueegg CS, Teuffel O,
Gumy -Pause F, Kuehni CE, Michel G, Swiss Paediatric Oncology G. Follow -Up Care of Adolescent Survivors of Childhood
Cancer: The Role of Health Beliefs. Pediatr Blood Cancer.
2016e; 63(2):318 -25.
8. Mader L, Rueegg CS, Vetsch J, Rischewski J, Ansari M, Kuehni CE, Michel G, Swiss Paediatric Oncology G. Employment
Situation of Parents of Long -Term Childhood Cancer Survivors. Plos ONE. 2016; 11(3):e0151966.
9. Mulder RL, van der Pal HJ, Levitt GA, Skinner R, Kremer
LC, Brown MC, Bardi E, Windsor R, Michel G, Frey E. Transition guidelines: An important step in the future care for
childhood cancer survivors. A comprehensive definition as
groundwork. Eur J Cancer. 2016; 54:64 -8.
10. Schindler M, Spycher BD, Ammann RA, Ansari M, Michel
G, Kuehni CE, Swiss Paediatric Oncology G, Swiss Paediatric
Oncology Group S. Cause -Specific Long -Term Mortality in
Survivors of Childhood Cancer in Switzerland: A Population
Based Study. Int J Cancer. 2016; 139(2):322 -33.
11. Vetsch J, Rueegg CS, Mader L, Bergstraesser E, Rischewski J, Kuehni CE, Michel G, Swiss Paediatric Oncology G.
Follow -up care of young childhood cancer survivors: attendance and parental involvement. Support Care Cancer.
2016; 24(7):3127 -38.
Swiss Childhood Cancer Registry Annual Report 2014/2015
12. Vienneau D, Infanger D, Feychting M, Schuz J, Schmidt LS,
Poulsen AH, Tettamanti G, Klaeboe L, Kuehni CE, Tynes T, Von
der Weid N, Lannering B, Roosli M. A multinational case -control study on childhood brain tumours, anthropogenic factors, birth characteristics and prenatal exposures: A validation of interview data. Cancer Epidemiol. 2016; 40:52 -59.
13. Wengenroth L, Sommer G, Schindler M, Spycher BD, von der
Weid NX, Stutz -Grunder E, Michel G, Kuehni CE, Swiss Paediatric Oncology G. Income in Adult Survivors of Childhood
Cancer. Plos ONE. 2016; 11(5):e0155546.
2015
14. Adam M, Kuehni CE, Spoerri A, Schmidlin K, Gumy -Pause
F, Brazzola P, Probst -Hensch N, Zwahlen M. Socioeconomic
Status and Childhood Leukemia Incidence in Switzerland.
Front Oncol. 2015; 5:139.
15. Adel Fahmideh M, Lavebratt C, Schuz J, Roosli M, Tynes T,
Grotzer MA, Johansen C, Kuehni CE, Lannering B, Prochazka
M, Schmidt LS, Feychting M. CCDC26, CDKN2BAS, RTEL1,
and TERT Polymorphisms in Pediatric Brain Tumor Susceptibility. Carcinogenesis. 2015; 36(8):876 -82.
16. Brown MC, Levitt GA, Frey E, Bardi E, Haupt R, Hjorth L,
Kremer L, Kuehni CE, Lettner C, Mulder RL, Michel G, Skinner R, on behalf of the PanCareSurFup C. The views of European clinicians on guidelines for long -term follow -up of
childhood cancer survivors. Pediatr Blood Cancer. 2015;
62:322 -328.
17. Gianinazzi ME, Rueegg CS, Zimmerman K, Kuehni CE, Michel
G, Swiss Paediatric Oncology G. Intra -Rater and Inter -Rater
Reliability of a Medical Record Abstraction Study on Transition of Care after Childhood Cancer. Plos ONE. 2015;
10(5):e0124290.
18. Hjorth L, Haupt R, Skinner R, Grabow D, Byrne J, Karner S,
Levitt G, Michel G, van der Pal H, Bárdi E, Beck J, de Vathaire
F, Essig S, Frey E, Garwicz S, Hawkins M, Jakab Z, Jankovic
M, Kazanowska B, Kepak T, Kremer L, Lackner H, Sugden E,
Terenziani M, Zadravec Zaletel L, Kaatsch P on behalf of the
PanCare Network. Survivorship after childhood cancer: PanCare: A European network to promote optimal long term
care. European Journal of Cancer.2015; 51(19), 1203–1211.
19. Lupatsch JE, Kuehni CE, Niggli F, Ammann RA, Egger M, Spycher BD. Population mixing and the risk of childhood leukaemia in Switzerland: a census -based cohort study. Eur J
Epidemiol. 2015b; 30(12):1287 -98.
20. Magi T, Kuehni CE, Torchetti L, Wengenroth L, Luer S,
Frei -Erb M. Use of Complementary and Alternative Medicine
in Children with Cancer: A Study at a Swiss University Hospital. Plos ONE. 2015; 10(12):e0145787.
21. Michel G, Vetsch J. Screening for psychological late effects
in childhood, adolescent and young adult cancer survivors: a
systematic review. Current Opinion in Oncology. 2015; 7(4),
297 -305.
22. Schindler M, Mitter V, Bergstraesser E, Gumy -Pause F, Michel G, Kuehni CE. Death certificate notifications in the Swiss
Childhood Cancer Registry: assessing completeness and registration procedures. Swiss Med Wkly. 2015; 145:w14225.
Publications
31
23. Spycher BD, Feller M, Roosli M, Ammann RA, Diezi M, Egger
M, Kuehni CE. Childhood cancer and residential exposure
to highways: a nationwide cohort study. Eur J Epidemiol.
2015d; 30(12):1263 -75.
24. Spycher BD, Lupatsch JE, Zwahlen M, Roosli M, Niggli F,
Grotzer MA, Rischewski J, Egger M, Kuehni CE, Swiss Pediatric Oncology G, Swiss National Cohort Study G. Background
ionizing radiation and the risk of childhood cancer: a census -based nationwide cohort study. Environ Health Perspect.
2015a; 123(6):622 -8.
25. Swerdlow AJ, Cooke R, Albertsson -Wikland K, Borgstrom B,
Butler G, Cianfarani S, Clayton P, Coste J, Deodati A, Ecosse
E, Gausche R, Giacomozzi C, Kiess W, Hokken -Koelega AC,
Kuehni CE, Landier F, Maes M, Mullis PE, Pfaffle R, Savendahl
L, Sommer G, Thomas M, Tollerfield S, Zandwijken GR, Carel JC. Description of the SAGhE Cohort: A Large European
Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone. Horm
Res Paediatr. 2015; 84(3):172 -83.
26. Vetsch J, Rueegg CS, Gianinazzi ME, von der Weid NX, Michel G. Information provision and information needs in parents of long -term childhood cancer survivors. Pediatr Blood
& Cancer. 2015; 62 (5), 859 -866.
27. Wengenroth L, Gianinazzi ME, Rueegg CS, Luer S, Bergstraesser E, Kuehni CE, Michel G. Health -related quality of
life in young survivors of childhood cancer. Qual Life Res.
2015a; 24(9):2151 -61.
28. Wengenroth L, Rueegg CS, Michel G, Gianinazzi ME, Essig
S, von der Weid NX, Grotzer M, Kuehni CE, Swiss Paediatric Oncology Group S. Concentration, working speed and
memory: Cognitive problems in young childhood cancer
survivors and their siblings. Pediatr Blood Cancer. 2015b;
62(5):875 -82.
2014
29. Essig S, Li Q, Chen Y, Hitzler J, Leisenring W, Greenberg M,
Sklar C, Hudson MM, Armstrong GT, Krull KR, Neglia JP,
Oeffinger KC, Robison LL, Kuehni CE, Yasui Y, Nathan PC.
Risk of late effects of treatment in children newly diagnosed
with standard -risk acute lymphoblastic leukaemia: a report
from the Childhood Cancer Survivor Study cohort. Lancet
Oncol. 2014; 15(8):841 -51.
30. Feijen EL, van der Pal HJ, van Dalen EC, Mulder RL, Bardi E,
Kuehni C, Tissing WJ, Kremer LC. A new method to facilitate valid and consistent grading cardiac events in childhood
cancer survivors using medical records. Plos ONE. 2014;
9(7):e100432.
31. Gianinazzi ME, Rueegg CS, von der Weid NX, Niggli FK,
Kuehni CE, Michel G, Swiss Paediatric Oncology G. Mental
health -care utilization in survivors of childhood cancer and
siblings: the Swiss childhood cancer survivor study. Support
Care Cancer. 2014b; 22(2):339 -49.
32. Gianinazzi ME, Essig S, Rueegg CS, von der Weid NX, Brazzola P, Kuehni CE, Michel G, Swiss Paediatric Oncology G.
Information provision and information needs in adult survivors of childhood cancer. Pediatr Blood Cancer. 2014a;
61(2):312 -8.
32
33. Hauri DD, Spycher B, Huss A, Zimmermann F, Grotzer M, von
der Weid N, Spoerri A, Kuehni CE, Roosli M, Swiss National
C, the Swiss Paediatric Oncology G. Exposure to Radio -Frequency Electromagnetic Fields From Broadcast Transmitters
and Risk of Childhood Cancer: A Census -based Cohort
Study. Am J Epidemiol. 2014; 179(7):843 -51.
34. Shu X, Prochazka M, Lannering B, Schuz J, Roosli M, Tynes
T, Kuehni CE, Andersen TV, Infanger D, Schmidt LS, Poulsen
AH, Klaeboe L, Eggen T, Feychting M. Atopic conditions and
brain tumor risk in children and adolescents - an international
case -control study (CEFALO). Ann Oncol. 2014; 25(4):902 -8.
35. Terenziani M, Spinelli M, Jankovic D, Bardi E, Hjorth L, Haupt
R, Michel G and Byrne J, on behalf of the PanCare Network.
Practices of pediatric oncology and hematology providers regarding fertility issues: A European Survey. Pediatric Blood &
Cancer. 2014; 61(11), 2054–2058.
36. Wengenroth L, Rueegg CS, Michel G, Essig S, Ammann RA,
Bergstraesser E, Kuehni CE, Swiss Paediatric Oncology G.
Life partnerships in childhood cancer survivors, their siblings,
and the general population. Pediatr Blood Cancer. 2014;
61(3):538 -45.
2013
37. Andersen TV, Schmidt LS, Poulsen AH, Feychting M, Roosli M, Tynes T, Aydin D, Prochazka M, Lannering B, Klaeboe
L, Eggen T, Kuehni CE, Schmiegelow K, Schuz J. Patterns of
exposure to infectious diseases and social contacts in early
life and risk of brain tumours in children and adolescents:
an International Case -Control Study (CEFALO). Br J Cancer.
2013; 108(11):2346 -53.
38. Gianinazzi ME, Rueegg CS, Wengenroth L, Bergstraesser E,
Rischewski J, Ammann RA, Kuehni CE, Michel G, for Swiss
Pediatric Oncology G. Adolescent survivors of childhood
cancer: are they vulnerable for psychological distress? Psychooncology. 2013c; 22(9):2051 -8.
39. Hauri D, Spycher B, Huss A, Zimmermann F, Grotzer M,
von der Weid N, Weber D, Spoerri A, Kuehni CE, Roosli M,
Swiss National C, Swiss Paediatric Oncology G. Domestic radon exposure and risk of childhood cancer: a prospective
census -based cohort study. Environ Health Perspect. 2013;
121(10):1239 -44.
40. Hauri DD, Huss A, Zimmermann F, Kuehni CE, Roosli M,
Swiss National C. Prediction of residential radon exposure
of the whole Swiss population: comparison of model -based
predictions with measurement -based predictions. Indoor
Air. 2013; 23(5):406 -16.
41. Rueegg CS, Gianinazzi ME, Michel G, von der Weid NX,
Bergstraesser E, Kuehni CE, Swiss Paediatric Oncology G. Do
childhood cancer survivors with physical performance limitations reach healthy activity levels? Pediatr Blood Cancer.
2013a; 60(10):1714 -20.
42. Rueegg CS, Gianinazzi ME, Rischewski J, Beck Popovic M,
von der Weid NX, Michel G, Kuehni CE. Health -related quality of life in survivors of childhood cancer: the role of chronic
health problems. J Cancer Surviv. 2013b; 7(4):511 -22.
43. Satgé D, Stiller C, Rutkowski S, Bueren A, Lacour B, Sommelet D, Nishi M, Massimino M, Garré M, Moreno F, Hasle
H, Jakab Z, Greenberg M, Weid N, Kuehni CE, Zurriaga O,
Vicente M -L, Peris -Bonet R, Benesch M, Vekemans M, Sullivan S, Rickert C. A very rare cancer in Down syndrome:
medulloblastoma. Epidemiological data from 13 countries.
J Neurooncol. 2013; 112(1):107 -14.
44. Singer S, Gianinazzi ME, Hohn A, Kuehni CE, Michel G.
General practitioner involvement in follow -up of childhood
cancer survivors: a systematic review. Pediatr Blood Cancer.
2013; 60(10):1565 -73.
45. Zimmermann K, Ammann RA, Kuehni CE, De Geest S, Cignacco E. Malnutrition in pediatric patients with cancer at diagnosis and throughout therapy: A multicenter cohort study.
Pediatr Blood Cancer. 2013; 60(4):642 -9.
2012
46. Aydin D, Feychting M, Schuz J, Roosli M, team Cs. Childhood brain tumours and use of mobile phones: comparison
of a case - control study with incidence data. Collaborators:
Tynes T, Andersen TV, Schmidt LS, Poulsen AH, Johansen
C, Prochazka M, Lannering B, Klæboe L, Eggen T, Jenni D,
Grotzer M, Von der Weid N, Kuehni CE. Environ Health.
2012; 11:35.
47. Christensen JS, Mortensen LH, Roosli M, Feychting M, Tynes
T, Andersen TV, Schmidt LS, Poulsen AH, Aydin D, Kuehni CE,
Prochazka M, Lannering B, Klaeboe L, Eggen T, Schuz J. Brain
tumors in children and adolescents and exposure to animals
and farm life: a multicenter case -control study (CEFALO).
Cancer Causes Control. 2012; 23(9).
48. Essig S, von der Weid NX, Strippoli MPF, Rebholz CE, Michel
G, Rueegg CS, Niggli FK, Kuehni CE. Health -related quality of life in long -term survivors of relapsed childhood acute
lymphoblastic leukemia: The Swiss Childhood Cancer Survivor Study. Plos ONE. 2012; 7(5):e38015.
49. Essig S, Skinner R, von der Weid NX, Kuehni CE, Michel G.
Follow -up programs for childhood cancer survivors in Europe: a questionnaire survey. Plos ONE. 2012; 7(12):e53201.
50. Hauri DD, Huss A, Zimmermann F, Kuehni CE, Roosli M. A
prediction model for assessing residential radon concentration in Switzerland. J Environ Radioact. 2012; 112:83 -9.
51. Kuehni CE, Strippoli MP, Rueegg CS, Rebholz CE, Bergstraesser E, Grotzer M, von der Weid NX, Michel G. Educational achievement in Swiss childhood cancer survivors
compared with the general population. Cancer. 2012a;
118(5):1439 -49.
52. Rebholz CE, Spycher BD, Rueegg CS, Michel G, Ammann R,
von der Weid NX, Kuehni CE. Clustering of health behaviours
in adult survivors of childhood cancer and the general population. Brit J Cancer. 2012; 107(2):234 -42.
53. Rebholz CE, Kuehni CE, Strippoli MPF, Rueegg CS, Michel G,
Hengartner H, Bergstraesser E, von der Weid NX. Alcohol
consumption and binge drinking in young adult childhood
cancer survivors: A report from the Swiss Childhood Cancer
Survivor Study. Pediatric Blood Cancer. 2012; 58:256 -64.
54. Rueegg CS, Michel G, Wengenroth L, von der Weid NX,
Bergstraesser E, Kuehni CE. Physical performance limitations
in adolescent and adult survivors of childhood cancer and
their siblings. Plos ONE. 2012a; 7(10):e47944.
Swiss Childhood Cancer Registry Annual Report 2014/2015
55. Rueegg CS, Rebholz CE, Michel G, Grotzer M, von der Weid
NX, Kuehni CE. Daily physical activity and sport of adult survivors of childhood cancer and healthy control. Plos ONE.
2012b; 7(4):e34930.
2011
56. Aydin D, Feychting M, Schuz J, Andersen TV, Poulsen AH,
Prochazka M, Klaeboe L, Kuehni CE, Tynes T, Roosli M. Predictors and overestimation of recalled mobile phone use
among children and adolescents. Prog Biophys Mol Biol.
2011; 107(3):356 -61. Epub 2011 /09 /13.
57. Aydin D, Feychting M, Schüz J, Andersen TV, Poulsen AH,
Prochazka M, Klaebo L, Kuehni CE, Tynes T, Roeoesli M. Impact of random and systematic recall errors and of selection
bias in case -control studies on mobile phone use and brain
tumors in adolescents (CEFALO study). Bioelectromagnetics.
2011; 32:396 -407.
58. Aydin D, Feychting M, Schüz J, Tynes T, Andersen TV,
Schmidt LS, Poulsen AH, Johansen C, Prochazka M, Lannering B, Klaeboe L, Eggen T, Jenni D, Grotzer M, Von der Weid
NX, Kuehni CE, Roeoesli M. Mobile phone use and brain tumors in children and adolescents: a multicenter case -control
study. J Natl Cancer Inst. 2011; 1264 -76.
59. Marquis A, Strippoli MPF, Spycher BD, Rebholz CE, von der
Weid NX, Kuehni CE. Paracetamol, NSAIDS and risk of asthma in adult survivors of childhood cancer. J Allergy Clin Immunol. 2011; 127:270 -2.
60. Michel G, Kuehni CE, Rebholz CE, Zimmermann K, Eiser C,
Rueegg CS, von der Weid NX. Can health beliefs help explaining attendance to follow -up care? The Swiss Childhood
Cancer Survivor Study. Psychooncology. 2011; 20:1034 -43.
61. Rebholz CE, Reulen RC, Toogood A, Frobisher C, Lancashire
ER, Winter DL, Kuehni CE, Hawkins M. Health care utilization
of long -term survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol. 2011; 29:4181 -8.
62. Rebholz CE, von der Weid NX, Michel G, Niggli F, Kuehni
CE. Follow -up care among long -term childhood cancer
survivors: a report from the Swiss childhood cancer survivor
study. Eur J Cancer. 2011; 41:221 -9.
63. Spycher BD, Feller M, Zwahlen M, Röösli M, von der Weid
NX, Hengartner H, Egger M, Kuehni CE. Childhood cancer
and nuclear power plants in Switzerland: a census -based
cohort study. Int J Epidemiol. 2011; 40:1247 -60.
2010
64. Adam M, von der Weid NX, Michel G, Zwahlen M, Lutz JM,
Probst -Hensch N, Niggli F, Kuehni CE. Access to specialized
pediatric cancer care in Switzerland. Pediatr Blood Cancer.
2010; 54:721 -7.
65. Feller M*, Adam M*, Zwahlen M, Brazzola P, Niggli F, Kuehni
CE. Family characteristics as risk factors for childhood acute
lymphoblastic leukemia. *joint first authorship. PLo One.
2010; 5; e13156.
66. Marquis, A, Kuehni CE*, Strippoli MPF, Kühne T, Brazzola
P, for the Swiss Pediatric Oncology Group (SPOG). Sperm
analysis of patients after successful treatment of childhood
acute lymphoblastic leukemia with chemotherapy only. *corresponding author. Pediatr Blood Cancer. 2010; 55:208 -10.
Publications
33
67. Michel G, Rebholz CE, von der Weid NX, Bergstraesser E,
Kuehni CE. Psychological distress in adult survivors of childhood cancer: the Swiss Childhood Cancer Survivor Study. J
Clin Oncol. 2010; 28:1740 -8.
2009
68. Spycher BD, Minder CE, Kuehni CE. Multivariate modelling
of responses to conditional items: New possibilities for latent
class analysis. Stat Med. 2009; 28:1927 -39.
2008
69. Michel G, von der Weid N, Zwahlen M, Redmond S, Strippoli MPF, Kuehni CE. Incidence of childhood cancer in Switzerland: the Swiss Childhood Cancer Registry. Pediatr Blood
Cancer. 2008; 50:46 -51.
2007
70. Michel G, von der Weid N, Zwahlen M, Adam M, Rebholz
CE, Kuehni CE. The Swiss Childhood Cancer Registry: rationale, organisation and results for the years 2001 -2005.
Swiss Med Wkly. 2007; 137:502 -9.
71. Röösli M, Michel G, Kuehni CE, Spoerri A. Cellular telephone
use and time trends in brain tumour mortality in Switzerland
from 1969 to 2002. Eur J Cancer Prev. 2007; 16:77 -82.
5.2 Editorials, commentaries and author replies
(Peer reviewed journals)
2015
72. Lupatsch JE, Egger M, Kuehni CE, Spycher BD. The authors’
reply: Population mixing and childhood leukaemia. Eur J Epidemiol. 2015c; 30(12):1333 -4.
73. Spycher BD, Roosli M, Egger M, Kuehni CE. “Author’s
Comment on ‘Background Ionizing Radiation and the Risk
of Childhood Cancer: A Census -Based Nationwide Cohort
Study’”. Environ Health Perspect. 2015b; 123(8):A198 -9.
74. Spycher BD, Roosli M, Egger M, Kuehni CE. Response to
“Comment on ‘Background Ionizing Radiation and the Risk
of Childhood Cancer: A Census -Based Nationwide Cohort
Study’”. Environ Health Perspect. 2015c; 123(8):A200 -1.
2012
75. Spycher BD, Kuehni CE, Zwahlen M, Egger M on behalf of
the Swiss National Cohort Study Group and the Swiss Paediatric Oncology Group. Authors’ response to: Childhood cancer and nuclear power plants in Switzerland: a census -based
cohort study. Int J Epidemiol. 2012; 41: 321 -322.
2006
76. Kuehni CE, Zwahlen M. Commentary: Numerous, heterogeneous and often poor – the studies on childhood leukaemia
and socioeconomic status. Int J Epidemiol. 2006; 35:384 -5.
34
5.3 Reviews (Peer reviewed journals)
2015
77. Bhatia S, Armenian SH, Armstrong GT, van Dulmen -den Broeder E, Hawkins MM, Kremer LC, Kuehni CE, Olsen JH, Robison LL, Hudson MM. Collaborative Research in Childhood
Cancer Survivorship: The Current Landscape. J Clin Oncol.
2015; 33(27):3055 -64.
78. Winther JF, Kenborg L, Byrne J, Hjorth L, Kaatsch P, Kremer
LC, Kuehni CE, Auquier P, Michel G, de Vathaire F, Haupt
R, Skinner R, Madanat -Harjuoja LM, Tryggvadottir L, Wesenberg F, Reulen RC, Grabow D, Ronckers CM, van Dulmen -den Broeder E, van den Heuvel -Eibrink MM, Schindler
M, Berbis J, Holmqvist AS, Gudmundsdottir T, de Fine Licht S,
Bonnesen TG, Asdahl PH, Bautz A, Kristoffersen AK, Himmerslev L, Hasle H, Olsen JH, Hawkins MM. Childhood cancer
survivor cohorts in Europe. Acta Oncol. 2015; 54(5):655 -68.
2014
79. Kuehni C, Spycher BD. Nuclear power plants and childhood
leukaemia: lessons from the past and future directions. Swiss
Med Wkly. 2014; 144:w13912.
80. Laurier D, Grosche B, Auvinen A, Clavel J, Cobaleda C, Dehos A, Hornhardt S, Jacob S, Kaatsch P, Kosti O, Kuehni C,
Lightfoot T, Spycher B, Van Nieuwenhuyse A, Wakeford R,
Ziegelberger G. Childhood leukaemia risks: from unexplained
findings near nuclear installations to recommendations for
future research. J Radiol Prot. 2014; 34(3):R53 -68.
2012
81. Kuehni CE, Rueegg CS, Michel G, Rebholz CE, Strippoli MP,
Niggli FK, Egger M, von der Weid NX. Cohort Profile: The
Swiss Childhood Cancer Survivor Study. Int J Epidemiol.
2012b; 41(6):1553 -64. Epub 2012 /06 /28.
2008
82. Adam M, Rebholz C, Egger M, Zwahlen M, Kuehni CE. Childhood Leukaemia and Socioeconomic Status: what is the evidence? Radiat Prot Dosim. 2008; 132:246 -54.
5.4 Publications (other journals)
Schweizer Krebsbulletin
Other
2016
83. Lupatsch JE, Kreis C, Niggli F, Kuehni CE, Spycher B. 2016.
Ursachen von Krebs bei Kindern: Was verrät der Wohnort?
Schweizer Krebsbulletin 2016a; 36(01): 29 -33.
2013
93. Mitter V, Michel G. Krebs bei Kindern. Ein Überblick aus dem
Schweizer Kinderkrebsregister. Onkologiepflege 1; 5 -8.
94. Ruegg CS, Gianinazzi ME, Michel G. Psychosoziale Spätfolgen nach Kinderkrebs – Eine Langzeitstudie des Schweizer
Kinderkrebsregisters. Newsletter Schweizerische Gesellschaft
für Psychoonkologie. 21; 5 -8.
95. Kuehni CE, Michel G, Egger M, Zwahlen M, Beck Popovic M,
Nigglie F, von der Weid NX. Das Schweizer Kinderkrebsregister: Erfahrungen als nationales Krebsregister. Schweizerische
Ärztezeitung 2013; 94: 327.
96. Kuehni CE, Niggli FK. Endlich ein nationales Krebsregistrierungsgesetz für Kinder und Erwachsene. Schweizerische
Ärztezeitung 2013; 94: 160.
2014
84. Wengenroth L, Schindler M, Kuonen R, Kuehni CE. Krebs als
Kind oder Teenager: das Leben danach. Schweizer Krebsbulletin 2014; 4: 292 -295.
85. Michel G, von der Weid NX. Nachsorge nach Krebs im
Kindesalter – Pläne für die Schweiz. Schweizer Krebsbulletin
2014; 4: 296 -298
2013
86. Kuehni CE, Mitter V, Niggli F, von der Weid NX. Die Rolle
des Kinderkrebsregisters unter dem geplanten Krebsregistrierungsgesetz: Chancen und Risiken. Schweizer Krebsbulletin 2013; 3:213 -216.
2012
87. Niggli F, Kuehni CE, Lamontagne -Müller S. Seltene Krebserkrankungen – das tägliche Brot der pädiatrischen Onkologie.
Schweizer Krebsbulletin. 2012; 4. 309 -10.
88. Michel G. Nachsorge nach Krebs im Kindesalter. Schweizer
Krebsbulletin. 2012; 3: 212 -213.
2010
89. Kuehni CE. The Swiss Childhood Cancer Registry: from causes to outcomes. Schweizer Krebsbulletin. 2010; 2:129 -130.
2009
90. Kuehni CE, Feller M, Egger M. Response to: Sufficient statistical power for CANUPIS? Bulletin suisse du cancer. 2009;
4.09:301.
2008
91. Kuehni CE, von der Weid NX, Hengartner H, Niggli F, Röösli
M, Huss A, Feller M, Egger M. CANUPIS – Childhood Cancer
and Nuclear Power Plants in Switzerland. Schweizer Krebsbulletin. 2008; 28: 264 -266.
92. von der Weid NX, Kuehni CE. Le Registre Suisse du Cancer
de l’Enfant: premier Registre du Cancer national. Information
de la communauté médicale quant à la nouvelle situation
concernant la protection des données. Bulletin des médecins
suisses. 2008; 89:117 -9.
Swiss Childhood Cancer Registry Annual Report 2014/2015
2008
97. Michel G. Nachsorge nach Krebs im Kindesalter – ein neues
Feld für Pflege?. Onkologiepflege 2011; 3: 20 -23.
98. Kuehni CE, von der Weid NX. Das Schweizer Kinderkrebsregister als erstes nationales Krebsregister: Information der
Ärzteschaft zur neuen Datenschutzsituation. Schweizerische
Aerztezeitung. 2008; 89:117 -9.
99. Kuehni CE, von der Weid NX. Das Schweizer Kinderkrebsregister als erstes nationales Krebsregister: Information der
Ärzteschaft zur neuen Datenschutzsituation. Paediatrica.
2008; 19:53 -5.
100. von der Weid NX, Kuehni CE. Le Registre Suisse du Cancer
de l’Enfant: premier Registre du Cancer national. Information
de la communauté médicale quant à la nouvelle situation
concernant la protection des données. Paediatrica. 2008;
19:50 -2.
2007
101. Kuehni CE. Children’s health and the environment. A global
perspective (Book review). Paediatrica 2007; 15:13 -28.
Publications
35
5.5 Reports
Annual Reports SCCR
Other Reports
2015
102. Schindler M, Mitter V, Pfeiffer V, Redmond S, Wölfli P, Kuonen
R, Sommer G, Spring M, Singh P, Michel G, Kuehni CE, The
Swiss Childhood Cancer Registry. Annual Report 2013 /2014.
Berne: Dept. of Social and Preventive Medicine, University of
Bern; March 2015.
2016
108. Arndt V, Feller A, Hauri D, Heusser R, Junker C, Kuehni CE,
Lorenz M, Pfeiffer V, Roy E, Schindler M. Schweizerischer
Krebsbericht 2015 – Stand der Entwicklungen. Bundesamt
für Statistik (BFS); Neuchâtel 2016.
2013
103. Mitter V, Michel G, Wölfli P, Gianinazzi M, Ruegg CS, Sommer G, Hau E, Kuehni CE, The Swiss Childhood Cancer Registry. Annual Report 2011 /2012. Berne: Dept. of Social and
Preventive Medicine, University of Bern; Feb 2013.
2011
104. Mitter V, Michel G, Strippoli MPF, Rebholz CE, Rueegg CS,
Viehmann G, Reck M, Niggli F, Hengartner H, von der Weid
NX, Kuehni CE. The Swiss Childhood Cancer Registry. Annual Report 2009 /2010. Bern: Dept. of Social and Preventive
Medicine, University of Bern; April 2011.
2009
105. Kuehni CE, Michel G, Pyrlic M, Strippoli MP, Adam M, Rebholz C, Rueegg C, Viehmann G, Reck M, Niggli F, Hengartern
H, von der Weid N. The Swiss Childhood Cancer Registry.
Annual Report 2007 /2008. Berne: Dept. of Social and Preventive Medicine, University of Bern; June 2009.
2007
106. Michel G, von der Weid NX, Adam M, Rebholz G, Zwahlen
M, Kuehni CE. The Swiss Childhood Cancer Registry. Annual Report 2005 /2006. Berne: Dept. Of Social and Preventive
Medicine, University of Bern; May 2007.
2005
107. Kuehni CE, Michel G, Sturdy M, Redmond S, Zwahlen M, von
der Weid N. The Swiss Childhood Cancer Registry. Annual
Report 2004. Bern: Dept. of Social and Preventive Medicine,
University of Bern; December 2005.
36
2011
109. Wyss N, Pury P, Strippoli MPF, Lutz JM, Bouchardy C, Kuehni
CE, Junker C. Krebs in der Schweiz – Stand und Entwicklung
von 1983 bis 2007. Bundesamt für Statistik (BFS); Neuchâtel
2011.
2005
110. Michel G, Sturdy M, Zwahlen M, Strippoli MPF, von der Weid
N, Kuehni CE. Validating date and cause of death information in the Swiss Childhood Cancer Registry against death
certificate information from the Swiss Federal Office of Statistics. Bern: Dept. of Social and Preventive Medicine, University
of Bern; December 2005.
6. Appendix: Classification of cancer diagnoses
International Classification of Childhood Cancer ICCC -3
The third edition of the International Classification of
Childhood Cancer (ICCC - 3) represents the standard for presentation of international data on childhood cancer incidence
and survival. It applies the rules, nomenclature and codes (morphology, topography and behaviour) of the ICD - O - 3. ICCC - 3
categories are defined in conformity with international classifications of the pathology and genetics of childhood cancers. In
the ICCC - 3, three hierarchical levels have been developed: level one consists of 12 main diagnostic groups and level two of
47 diagnostic subgroups. These two levels of the ICCC - 3 allow
standardised comparison of the broad categories of childhood
tumours. Level three, an optional «extended» classification,
comprises two to eleven divisions of selected diagnostic subgroups. The division of some diagnostic subgroups, e.g. leukaemia and Non - Hodgkin lymphomas, reflects the availability
of detailed cytogenetic or molecular information that permits
homogeneous groups of tumours to be distinguished within
them and thus allows their separate study. The Swiss childhood
cancer registry (SCCR) uses level one to three. Only malignant
neoplasms are classified in ICCC - 3, with the exception of
non - malignant intracranial and intraspinal tumours. Tumours
known to occur only rarely in young patients are also included
in ICCC - 3. The ICCC - 3 is used if data are compared with other
childhood cancer registries.
characters for topography (based on the malignant neoplasm
section of ICD - 10). The topography code remains the same for
all neoplasms of that site. The behaviour code is incorporated
as the fifth digit in the morphology field. It identifies whether
the tumour is malignant, benign, of uncertain or unknown behaviour, in situ, presumed to be primary or secondary. For all
tumours diagnosed since 1st January 2014 the SCCR uses the
2011 updates to ICD - O - 3 which include new terms, codes
and behaviour combinations. This allows e.g. B lymphoblastic leukaemias to be further classified according to their exact
cytogenetic and molecular characteristics, which are relevant
for disease prognosis. ICD - O - 3 is used to compare data with
general cancer registries.
International Statistical Classification of Diseases
and Related Health Problems - ICD -10
The third edition of the International Statistical Classification of Diseases for Oncology (ICD - O - 3) has been developed
by a working group hosted by the International Association of
Research in Cancer (IARC) and WHO. The morphology code for
neoplasm has been revised, especially for lymphomas and leukaemia. In contrast to the International Classification of Diseases, 10th revision (ICD - 10), ICD - O - 3 uses only one set of four
The International Statistical Classification of Diseases and
Related Health Problems (ICD) permits the systematic recording, analysis, interpretation and comparison of mortality and
morbidity data collected in different regions and at different
time periods. The ICD has become the international standard
diagnostic classification for all general epidemiological purposes. The ICD - 10 classification comprises three volumes: Volume
1 contains the main classifications; Volume 2 provides guidance for users of the ICD; and Volume 3 is the alphabetical index to the classification. Classification is divided into 21 chapters. The first character of the ICD code is a letter. Each letter
is associated with a particular chapter, e.g. the letter D is used
in both chapter II «Neoplasms» and chapter III «Diseases of the
blood and blood - forming organs and certain disorders involving the immune mechanism». The topography code in Volume
3 describes the site and the behaviour of the neoplasm: malignant, secondary or metastatic, in situ, benign or of unknown
behaviour. The morphology codes listed in Volume 1 are the
same as those used in the special adaptation of the ICD for
oncology, the ICD - O97.
Swiss Childhood Cancer Registry Annual Report 2014/2015
Appendix: Classification of cancer diagnoses
International Statistical Classification of Diseases for
Oncology - ICD -O -3
37
38
© 2016 Swiss Childhood Cancer Registry
Logo: Elsbeth Kuehni, Bern
Layout: HP Hauser, Bern